Synthesis, Biological Evaluation and Mechanism Studies of Deoxytylophorinine and Its Derivatives as Potential Anticancer Agents by Lv, Haining et al.
Synthesis, Biological Evaluation and Mechanism Studies
of Deoxytylophorinine and Its Derivatives as Potential
Anticancer Agents
Haining Lv
., Jinhong Ren
., Shuanggang Ma, Song Xu, Jing Qu, Zhenjia Liu, Qing Zhou, Xiaoguang
Chen*, Shishan Yu*
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union
Medical College, Beijing, China.
Abstract
Previous studies indicated that (+)-13a-(S)-Deoxytylophorinine (1) showed profound anti-cancer activities both in vitro and
in vivo and could penetrate the blood brain barrier to distribute well in brain tissues. CNS toxicity, one of the main factors to
hinder the development of phenanthroindolizidines, was not obviously found in 1. Based on its fascinating activities, thirty-
four derivatives were designed, synthesized; their cytotoxic activities in vitro were tested to discover more excellent
anticancer agents. Considering the distinctive mechanism of 1 and interesting SAR of deoxytylophorinine and its
derivatives, the specific impacts of these compounds on cellular progress as cell signaling transduction pathways and cell
cycle were proceeded with seven representative compounds. 1 as well as three most potent compounds, 9, 32, 33, and
three less active compounds, 12, 16, 35, were selected to proform this study to have a relatively deep view of cancer cell
growth-inhibitory characteristics. It was found that the expressions of phospho-Akt, Akt, phospho-ERK, and ERK in A549 cells
were greater down-regulated by the potent compounds than by the less active compounds in the Western blot analysis. To
the best of our knowledge, this is the first report describing phenanthroindolizidines alkaloids display influence on the
crucial cell signaling proteins, ERK. Moreover, the expressions of cyclin A, cyclin D1 and CDK2 proteins depressed more
dramatically when the cells were treated with 1, 9, 32, and 33. Then, these four excellent compounds were subjected to flow
cytometric analysis, and an increase in S-phase was observed in A549 cells. Since the molecular level assay results of Western
blot for phospho-Akt, Akt, phospho-ERK, ERK, and cyclins were relevant to the potency of compounds in cellular level, we
speculated that this series of compounds exhibit anticancer activities through blocking PI3K and MAPK signaling
transduction pathways and interfering with the cell cycle progression.
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Introduction
Phenanthroindolizidine alkaloids are pentacyclic natural prod-
ucts isolated mainly from plants belonging to Cynanchum, Pergularia,
Tylophora as well as some genera of the Asclepiadaceae [1–3]. For
many years, these natural products and synthetic derivatives
attract widespread attention for their extensively therapeutic
activities, such as anticancer activity [4–8], anti-inflammatory
activity [9–11], antibacterial activity [12–14], and so on. However,
the specific biomolecular targets of these compounds on cell
growth have not been clearly identified until now. Early studies
illustrated that phenanthroindolizidine alkaloids could inhibit
RNA, DNA synthesis, and inhibited protein synthesis at the
elongation stage of the translation procedure by locating on 40S
ribosomal component [15–20]. Recently, some possible targets
were reported, including metabolic enzymes [21–23] and some
elements engaged in gene transcription [24,25]. Moreover, recent
research demonstrated that these compounds with similar
structures may act on different targets [26]. Although the
biological activities of these compounds are affirmative, there are
some side effects limiting their application as anticancer drugs,
especially CNS toxicity arose in natural tylocrebrine obviously for
disorientation and ataxia [27]. And as far as we know, there is not
a phenanthroindolizidine alkaloid applied in clinical application
up to now. Therefore, it is very pressing to discover novel
phenanthroindolizidine alkaloids with profound anticancer activity
and reduced CNS toxicity as drug candidates.
(+)-13a-(S)-Deoxytylophorinine (1), originally isolated from the roots
of Tylophora atrofolliculata and Tylophora ovata in our laboratory (Patent
Publication Number: CN101058578A; PCT/CN2010/075083), was
found to have profound anti-cancer activities, both in vitro and in vivo
[28]. Liu et al [29] discovered that this compound could penetrate the
blood brain barrier and distribute in brain tissues without obvious
CNS toxicity. Further study confirmed that 1 could interact with
DNA and RNA dose-dependently and preferred to intercalate into
AT-repeated base pair in double-helical DNA sequences.
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were designed and synthesized in our present research. The
potential cytotoxic activities of these synthetic compounds against
series of human cancer cells in vitro were assessed and the
preliminary structure-activity relationships (SAR) were summa-
rized.
1 could interact with DNA and RNA and concomitantly block
the process of transcription to produce the anticancer effects in
Liu’s research [28,29]. And high concentrations of 1 could induce
cell apoptosis (Figure S1). Previous study indicated that phospha-
tidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase
(MAPK) signaling pathways play a fundamental role in the
apoptosis induced by DNA-damaging drugs [30]. Furthermore,
only a little information is available regarding the regulation of the
PI3K and MAPK signaling transduction pathways in the context
of phenanthroindolizidine-induced apoptosis [31–34]. Thus, we
are inspired to further study the specific impacts of deoxytylo-
phorinine and its derivatives on cell progression as cell signaling
transduction pathways and cell cycle. Our study represent a
significant step forward in understanding of the cell signaling
transduction pathways and cell cycle associated with the apoptosis
elicited as the result of exposure to DNA-damaging anticancer
agents of deoxytylophorinine and its derivatives.
Results and Discussion
Design and synthesis of deoxytylophorinine derivatives
To investigate the influence of the steric propterty at C-13a on
cytotoxic activity, enantiomer of 1 ((2)-13a-(R)-deoxytylophor-
inine (2)), which was previously isolated from the roots of Pergularia
pallida plants [35], was synthesized. The amide intermediates were
also screened against cancer cell lines to determine the impact of
electric property at N-10. With respect to the substituted pattern
on phenanthrene ring, derivatives with methoxyl groups in
different locations, different number of substitutes, or other
substitute such as F in phenanthrene ring were designed. Methoxyl
group, amino group, or substituted amino groups were connected
to C-14 to reveal the impacts, including the volume of the
substitutes at C-14, on cytotoxic activities.
Using L-glutamate as chiral building block, 1 was prepared with
higher ee value than previous reports [36,37] based on Rapoport’s
[38] and Ikeda’s [39] routes accompanied with some improvement
in our synthetic research. As depicted in Figure 1, after
condensation, esterification, oxidative cyclization, and reduction
[40,41], the key intermediate d was iodized and then condensed in
situ with L-glutamate to produce f. Subsequently, g was
synthesized through cyclization and hydrolysis. From d to g,
product in each step can be used directly in the next reaction
without purification to facilitate the experiment operation in our
research. After Friedel-Crafts acylation and reduction with
NaBH4, i was treated with Et3SiH and BF3?Et2O to give j, which
was a new strategy to avoiding racemization at C-13a. Finally, the
target compound 1 was obtained by reduction with LiAlH4 in
refluxing THF, with 99% ee value and 7% total yield. Thirty-four
derivatives were subsequently designed and prepared with this
synthetic strategy.
For the synthesis of 2, same materials and procedures were
applied as synthesis of 1 except for the chiral building block of D-
glutamate. And five derivatives (3 [38], 4 [42], 5, 6 [43], and 7
[43]) with different substitutes at phenanthrene ring of 1 were
synthesized with several different substituted benzaldehydes and
phenylacetic acids.
14-methoxyl derivatives can be synthesized from the interme-
diate of i. After methylation, the resulting diastereoisomer mixture
could be isolated by silica gel column chromatography to afford k
and l. The absolute configuration of C-14 could be verified by
1H-
NMR. For the intermediate of k, H-14 appears as doublet
(J=7.0 Hz) at 5.15 ppm, since the dihedral angel between H-13a
and H-14 was close to 180u [38]. Thus we confirmed the
configuration of C-14 was R in k. While broad singlet at 5.19 ppm
was observed for H-14 in the intermediate of l, inferring S
configuration in this position. This conclusion was further
confirmed by NOE measurement of k and l (Figure S2). The
target derivatives 8 (13aS,1 4 R) and 9 [44] (13aS,1 4 S) were
obtained by reduction of k and l respectively. Their enantiomers
10 (13aR,1 4 S) and 11 (13aR,1 4 R) could be prepared from the
enantiomer of i by the same procedures.
Reductive amination was applied to introduce substituted-
amino groups at C-14. h was reacted with substituted amines to
produce the corresponding imines [46], which were subsequently
treated with NaBH4 to afford diastereoisomer mixtures of m and
n. After isolated from chromatography, m and n were reduced to
corresponding derivatives by LiAlH4. Twenty four new derivatives
with optically pure properties at C-13a and C-14 were synthesized
through this synthetic strategy.
Biology
Since 1 exerted profound cytoxoic activities in vitro [28], its
derivatives and five synthetic intermediates (f, g, h, i, and j)
(Table 1) were screened against seven human cancer cell lines in
this research to explore their cytotoxic spectra and to discover
more potent compounds. Preliminary mechanistic studies, includ-
ing the influence on cell signaling transduction pathways and cell
cycle, were thus performed in order to reveal a more detailed
picture on the possible targets.
Evaluation of deoxytylophorinine derivatives against
human cancer cell lines in vitro and summary of
preliminary SAR study
Two optically pure deoxytylophorinines, their derivatives and
five synthetic intermediates were screened for cytotoxicity against
seven human tumor cell lines in vitro: HCT8 (human colon cancer
cell line), U251 (human glioblastoma cancer cell line), HepG2
(human hepatocellular cancer cell line), A549 (human lung
adenocarcinoma cell line), A2780 (human ovarian cancer cell
line), BGC823 (human gastric cancer cell line) and Capan2
(human pancreatic cancer cell line) by MTT assay and preliminary
SAR results were also outlined. HCT8, HepG2, A549, and
Capan2 were obtained from ATCC (Virginia, USA) and U251,
A2780, and BGC823 were obtained from Cell Culture Center,
Institute of Basic Medical Sciences, Chinese Academy of Medical
Sciences & Peking Union Medical College (Beijing, China).
As summarized in Table 2, the five synthetic intermediates were
inactive in all cell lines, with IC50 value more than 10 mM.
Interestingly, j, the amide derivative of 1, possessed dramatically
decreased potency. The ketone group at C-11 in j changes the
tertiary amine in the indolizidine nucleus to an amide, decreasing
the electron density at nitrogen-atom which may be important in
the electrostatic interaction with the target. Such a finding is in
agreement with the previous reports that C-9 amide structures of
various phenanthroindolizidines were much less potent in cancer
cell growth assays [8,47]. Other synthetic intermediates, h and i,
also confirmed this conclusion and displayed significantly reduced
activities.
As substitutes in phenanthrene ring to be concerned, a tempting
phenomenon can be seen that 3, 5 with methoxyl group at C-2 in
the phenanthrene ring were higher selective than 1 toward various
Research on Deoxytylophorinine and Derivatives
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7 without any substitute at this position, exhibited comparative
activity to the parent structure.
For the 3, 6, 7-trimethoxyl derivatives, the steric properties of C-
13a and the volume of substitutes at C-14 are two crucial factors
influencing their potency. As summarized in Table 2, 1 with S
configuration at C-13a exerted profound cytotoxic activities against
all of the cancer cells in vitro, and were about 10-fold more potent
than its enantiomer 2. Coincident results were observed for 9 and
10, 32 and 35, 33 [45] and 34, confirming that the steric propterty
of C-13a play a significant role in cytotoxic activities. Bearing
methoxyl group at the C-14 with S configuration, 9 showed about a
10-fold increased potency compared to the precursor 1. Positioning
of the amino group at the C-14, no matter what configuration is,
leads to a remarkable enhancement of cytotoxic abilities against
several cancer cell lines, as 32 and 33 with IC50 ranging from 15 to
40 nM were much stronger than their parent structure and the
positive control of Doxorubicin. However, when the amino group
connected with other substituents, neither linear nor circular, the
cytotoxic activities decreased dramatically, as can bee seen in 12–
31. 9, 32, and 33 exhibited greater cytotoxic activity than 1,
indicating that bearing small group at C-14 could improve the
parent-compound efficacy. Therefore, keeping S configuration at
C-13a and bearing small group at C-14 were necessary for the
enhancement of their potency.
The above initial SAR results may be helpful for the subsequent
structure modification to design novel and potent cytotoxic
deoxytylophorinine derivatives.
Since 1 was confirmed to interact with DNA and RNA [28,29],
what will happen to the down-stream cellular processes? Based on
previous reports that PI3K and MAPK signaling transduction
pathways played a fundamental role in the apoptosis induced by
DNA-damaging drugs, we investigated the influence of deoxyty-
lophorinine derivatives on these two signaling transduction
pathways. Moreover, PI3K and MAPK signaling transduction
pathways have emerged as promising molecular targets in the
prevention of cancers, by influencing a large variety of cellular
processes, such as cell apoptosis, survival, and cell-cycle regulation
[48,49]. Subsequently, the influence of these compounds on cell-
cycle regulation was also studied as objects to explore the
antitumor effects and mechanisms. Besides 1, three most potent
compounds 9, 32, 33 and three less active compounds 12, 16, 35
were chosen to process this research.
Effects of 1, 9, 12, 16, 32, 33 and 35 on the PI3K and
MAPK signaling transduction pathway in A549 cells
The PI3K signaling pathway is probably the best characterized
and most prominent pathway with regard to the transmission of
anti-apoptotic signals in cell survival [49,50]. The MAPK
signaling transduction pathway is also known to play crucial roles
in cell progressions [48]. The Western blot analysis results
indicated that deoxytylophorinine derivatives could influence
PI3K signaling pathway, since incubation of A549 cells with
500 nM of potent compounds 1, 9, 32, and 33 could trigger the
down-regulation of phospho-Akt and total-Akt compared with that
in the control and in less active compounds 12, 16, and 35.A sa
higher expression of phospho-Akt and Akt is linked to proliferation
pathways, this down-regulatory property of tested compounds
might contribute to their anticancer action. We also examined
whether selected compounds had an inhibition on mitogen-
Figure 1. Synthesis of deoxytylophorinine and its derivatives.
doi:10.1371/journal.pone.0030342.g001
Research on Deoxytylophorinine and Derivatives
PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e30342activated protein kinase ERK activity by Western blot assay. As
illustrated in Figure 2, the potent compounds 1, 9, 32, and 33 also
exerted more notable inhibitory effects on ERK phosphorylation
than other groups. Since potent compounds against tested cancer
cell lines consistently exhibited intense suppression of Akt and
ERK activation than the less active compounds, we can deduce
that the potent inhibitory effects of these compounds on the two
signaling transduction pathways may be means of their anticancer
activities. Thus, we have provided novel insight into the
understanding of the underlying molecular mechanisms of these
synthesized phenanthroindolizidine alkaloids.
Effects of 1, 9, 12, 16, 32, 33, and 35 on the cell cyclins in
A549 cells
It is well known that cell proliferation is generally regulated by
controlling cell cycle progression through promoting or inhibiting
the activities of cyclins/cyclin-dependent kinases (CDKs) complexes
or their associated proteins [51]. The seven selected typical
compounds (1, 9, 12, 16, 32, 33,a n d35) were then evaluated
for their effects on the regulatory proteins responsible for cell cycle
progression, such as cyclin A, cyclin B1, cyclin D1 and cyclin E in
A549 cells. 1, 9, 32,a n d33 show more remarkable down-
regulation of cyclin A, cyclin D1 and CDK2 than the control and
the less active compounds 12, 16, and 35 (Figure 3), parallel to the
results in the cytotoxicity assay, whereas the level of the cyclin B1
and cyclin E did not change significantly. Cyclin D1 overexpression
has been observed in a number of human tumors and is associated
with poor prognosis and chemoresistance. Therefore, the down-
regulatory effect of cyclin D1 also contributes to the antitumor
activity of these potent compounds, and this conclusion was in
agreement with previous reports by Gao et al [26]. These results
indicate that these compounds inhibit cell growth through the
interruption of some proteins involved in the cell cycle progression.
Induction of S-phase arrest in A549 cells by 1, 9, 32, and
33
Cell cycle modulators that halt uncontrollable tumor growth are
regarded as highly promising therapeutic agents against human
cancers. Many natural products exhibited growth inhibitory
activities on cancer cells through cell cycle regulation [24,52].
Based on the results that 1, 9, 32, and 33 were potent compounds
at inhibiting cell growth and reducing the expressions of cyclin A,
cyclin D1 and CDK2, we further explored the effects of these four
compounds on cell cycle distribution by flow cytometric assay.
As revealed by flow cytometric analysis (Table 3), suppression of
cell proliferation with 500 nM of those four potent compounds was
accompanied by the significant accumulation of cells in the S-phase
in A549 cells as compared with the control. For instance, cell
populations in the G0/G1,S ,G 2/M (%) phases were 59.95%,
31.25%, and 8.80% respectively in the control group. However,
a f t e re x p o s u r et oc o m p o u n d s1, 9, 32,a n d33 for 24 h, cell
populations in the S-phase were noticeably enhanced by 6%, 14%,
18%, and 11% respectively. Student’s t test was used to examine the
significance of the values. For S-phase in A549 cells, statistical
analysis results were: 1 compared with control, P,0.01; 9 compared
with control, P,0.05; 32 compared with control, P,0.05; and 33
compared with control, P,0.05. This increase in the proportion of
cells in the S-phase was accompanied by a concomitant decreased
proportion of cells in the G0/G1 and G2/M phase.
The SubG0/G1 content of DNA is typically indicative of
apoptosis. Form the flow cytometric analysis, we can see the
proportion of cells in SubG0/G1 phase didn’t differ significantly
Table 1. Structures of deoxytylophorinine, its intermediate
and derivatives.
Compd
a R
1 R
2 R
3 R
4 R
5 R
6
f H OMe OMe OMe H (S)-
g H OMe OMe OMe H (S)-
h H OMe OMe OMe H (S)-
i H OMe OMe OMe H (S)O H
j H OMe OMe OMe H (S)H
k H OMe OMe OMe H (S) OMe (R)
l H OMe OMe OMe H (S) OMe (S)
m H OMe OMe OMe H (S) BnNH (R)
n H OMe OMe OMe H (S) BnNH (S)
1 H OMe OMe OMe H (S)H
2 H OMe OMe OMe H (R)H
3 OMe OMe OMe OMe H (S)H
4 OMe OMe OMe H H (S)H
5 OMe H OMe OMe H (S)H
6 H F OMe OMe H (S)H
7 H H OMe OMe H (S)H
8
b H OMe OMe OMe H (S) OMe (R)
9 H OMe OMe OMe H (S) OMe (S)
10 H OMe OMe OMe H (R) OMe (S)
11 H OMe OMe OMe H (R) OMe (R)
12
b H OMe OMe OMe H (S) BnNH (R)
13
b H OMe OMe OMe H (S) BnNH (S)
14 H OMe OMe OMe H (R) BnNH (S)
15 H OMe OMe OMe H (R) BnNH (R)
16
b H OMe OMe OMe H (S) n-PrNH (R)
17
b H OMe OMe OMe H (S) n-PrNH (S)
18 H OMe OMe OMe H (R) n-PrNH (S)
19 H OMe OMe OMe H (R) n-PrNH (R)
20
b H OMe OMe OMe H (S) i-PrNH (R)
21
b H OMe OMe OMe H (S) i-PrNH (S)
22 H OMe OMe OMe H (R) i-PrNH (S)
23 H OMe OMe OMe H (R) i-PrNH (R)
24
b H OMe OMe OMe H (S) c-PentylNH (R)
25
b H OMe OMe OMe H (S) c-PentylNH (S)
26 H OMe OMe OMe H (R) c-PentylNH (S)
27 H OMe OMe OMe H (R) c-PentylNH (R)
28
b H OMe OMe OMe H (S) c-HexylNH (R)
29
b H OMe OMe OMe H (S) c-HexylNH (S)
30 H OMe OMe OMe H (R) c-HexylNH (S)
31 H OMe OMe OMe H (R) c-HexylNH (R)
32
b H OMe OMe OMe H (S)N H 2 (R)
33
b H OMe OMe OMe H (S)N H 2 (S)
34 H OMe OMe OMe H (R)N H 2 (S)
35 H OMe OMe OMe H (R)N H 2 (R)
aCompounds 1 [36,37], 2 [35], 3 [38], 4 [42], 6 [43], 7 [43], 9 [44], and 33 [45] are
known, while others are new synthesized.
bThese compounds have been claimed in a pending patent (PCT/CN2010/
070832).
doi:10.1371/journal.pone.0030342.t001
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these compounds for 24 h in A549 cells.
1, 9, 32, and 33 blocked S-G2 transition, resulting in S-phase
accumulation, thereby delaying the progression of cells through
G2/M phase in A549 cells. This result is consistent with the
expression levels of cyclin A/CDK2 detected by Western blot
assay, since this complex is the primary promoter of the G2 phase.
Thus we speculated that the S phase blockage of cell cycle
Table 2. Cytotoxic activities of deoxytylophorinine and its derivatives in vitro.
IC50
a(mM)
Compd HCT8 U251 HepG2 A549 A2780 BGC823 Capan2
f .10
**, ## .10
**, ## .10
**, ## .10
**, ## .10
**, ## .10
**, ## .10
**, ##
g .10
**, ## .10
**, ## .10
**, ## .10
**, ## .10
**, ## .10
**, ## .10
**, ##
h .10
**, ## .10
**, ## .10
**, ## .10
**, ## .10
**, ## .10
**, ## .10
**, ##
i .10
**, ## .10
**, ## .10
**, ## .10
**, ## .10
**, ## .10
**, ## .10
**, ##
j .10
**, ## .10
**, ## .10
**, ## .10
**, ## .10
**, ## .10
**, ## .10
**, ##
1 0.3160.19 0.3460.14 0.1360.10 0.1460.08 0.2760.20 1.1761.17 0.3460.19
2 1.5460.86 1.3460.77 1.0860.70 1.7461.08 2.8260.23
**, ## 8.5462.53
*, ## 1.9061.22
3 0.2960.13 0.8960.63 0.7560.57 4.7762.85* .10
**, ## 9.3161.19
**, ## 8.9261.87
**, ##
4 2.2561.48 1.4260.97 0.7960.21
**, # 1.2760.74 5.5264.00 7.7962.19
**, ## 0.6160.30
5 0.4260.08 1.7361.00 1.1961.15 2.7161.52
*,# 9.2760.63
**, ## 7.3064.67 .10
**, ##
6 0.2260.17 0.3860.15 0.2660.14 0.2760.08 0.1960.14 0.4260.05 0.9260.75
7 0.2560.11 0.4160.17 0.2260.03 0.4260.18 .10
**, ## 0.5960.19 0.6960.20
8 4.2960.85
**, ## 3.1461.51
*, # 3.2560.77
**, ## 4.5761.26
**, ## 8.0561.99
**, ## 9.4960.55
**, ## 6.7063.02
*, #
9 0.0560.01
# 0.0760.05
* 0.1560.16 0.0760.03 0.0860.02
# 0.0860.03 0.1960.21
10 0.4560.08 0.7060.33
# 0.4460.17 2.6561.52
* 8.8262.04
**, ## 6.5863.79 2.7960.99
*
11 3.0960.98
**, # 4.6961.96
*, # 0.9860.56 2.0961.15
*, # 7.5962.50
**, ## 6.7763.39
# 1.9961.48
12 1.8561.21 2.3661.74 2.5261.13
*, # 4.9861.80
**, # 3.9360.94
**, ## 6.8862.94
*, # 4.0361.97*
13 5.5960.32
**, ## 3.3560.97
**, ## 4.0060.41
**, ## 4.8461.18
**, ## 8.8761.96
**, ## 9.8560.26
**, ## 6.6760.54
**, ##
14 3.1761.62
* 3.5661.19
**, ## 3.0960.85
**, ## 4.5261.94
*, # 8.3162.55
**, ## 7.4462.55
*, # 6.3061.24
**, #
15 7.7763.86
*, # 6.3863.16
*, # 9.0361.69
**, ## 7.6162.38
**, ## .10
**, ## .10
**, ## 9.1461.50
**, ##
16 5.3561.60
**, ## 2.7761.59
# 3.0260.92
**, ## 3.7160.72
**, ## 8.7262.21
**, ## 7.2963.35
*, # 3.1361.16
*
17 5.5761.05
**, ## 3.1760.79
**, ## 3.8760.63
**, ## 4.9160.84
**, ## 6.8162.62
*, # 9.3861.08
**, ## 4.0761.26
**
18 2.9361.47
* 2.1361.02
*, # 2.4060.76
**, ## 2.8361.39
*, # 5.5163.32 5.0764.27 9.0261.03
**, ##
19 7.0661.72
**, ## 5.1460.90
**, ## 4.1060.79
**, ## 5.2761.21
**, ## 9.2061.39
**, ## 9.5060.86
**, ## 6.3663.33
*
20 4.7260.36
**, ## 4.0260.31
**. ## 4.8861.64
**, ## 4.2661.03
**, ## 6.6661.02
**, ## 7.9561.79
**, ## 5.8162.43
*
21 4.9560.40
**, ## 3.2460.74
**, ## 4.2761.17
**, ## 4.0661.33
**, ## 4.7760.92
**, ## 8.2661.77
**, ## 5.0861.49
**, #
22 3.0160.97
**, # 2.6360.63
**, ## 2.4560.62
**, ## 3.3460.73
**, ## 3.3360.83
**, ## 4.5562.78 3.6762.85
23 7.6962.01
**, ## 8.2061.05
**, ## 5.0960.75
**, ## 7.3363.42
*, # .10
**, ## 9.3161.19
**, ## 6.3063.25
*
24 4.1761.30
**, ## 3.5161.83
*, # 2.3461.39 3.1861.57
*, # 6.6763.06
*, # 7.6062.14
*, ## 4.1061.30
**
25 5.6860.97
**, ## 3.3060.69
**, ## 2.8560.35
**, ## 3.9160.40
**, ## 5.2161.08
**, ## 7.7762.13
**, ## 6.4461.26
**, #
26 5.8662.31
*, # 5.6161.56
**, ## 4.5461.30
**, ## 4.6460.96
**, ## 9.2561.29
**, ## .10
**, ## 7.4261.66
**, #
27 5.7461.08
**, ## 4.6261.34
**, ## 3.7761.31
**, ## 6.3263.44
*, # 6.2162.73
*, # 8.5161.30
**, ## 8.0263.42
*, #
28 4.8160.94
**, ## 4.5160.59
**, ## 3.3660.83
**, ## 5.9663.34
*, ## 8.4661.81
**, # 7.4662.61
*, # 8.2961.57
**, ##
29 3.7661.51
*, # 3.2360.79
**, ## 3.4561.38
*, # 6.0563.52
*, # 4.6160.16
**, ## 7.4262.66
*, # 5.7762.62
*
30 4.5860.75
**, ## 3.8261.28
**, ## 3.4861.16
**, ## 4.9261.84
*, # 4.8360.34
**, ## 6.0263.45 8.1462.07
**, #
31 5.9761.25
**, ## 3.7660.30
**, ## 3.4060.27
**, ## 5.9063.43
*, # 7.8661.95
**, ## 6.1760.14
**, ## 9.5060.86
**, ##
32 0.0260.02
# 0.0560.01
* 0.0560.01 0.0760.02 4.5661.23
**, ## 0.1160.11 0.4260.30
33 0.0360.01
# 0.0460.01
* 0.0260.01 0.4060.15 0.0560.04,
# 0.2660.13 0.4360.21
34 7.6060.52
**, ## 6.2761.02
**, ## 6.7562.81
*, # 6.9462.72
*, # 9.2061.39
**, ## .10
**, ## 4.7060.59
**, #
35 3.9761.03
**, ## 3.8960.00
**, ## 5.7863.67 4.6161.15
**, ## 6.6963.43
*, # 9.0561.28
**, ## 3.3160.70
**
Doxorubicin 0.6160.25 0.1360.09 0.2360.25 0.2360.16 0.6360.27 0.9760.92 1.5761.45
aIC50 values are the test compounds concentration (mM) that inhibited the cell growth by 50%. Data represent the mean values 6 standard deviation of three
dependent experiments performed in triplicate (*, p,0.05 compared with compound 1; **, p,0.01 compared with compound 1;
#,p ,0.05 compared with
Doxorubicin;
##,p ,0.01 compared with Doxorubicin). These IC50 values were all measured for 72 h treatment. IC50 values for 24 h treatment were in Table S1.
doi:10.1371/journal.pone.0030342.t002
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growth inhibition of deoxytylophorinine and its derivatives.
Materials and Methods
Synthesis
THF was distilled from sodium and benzophenone, acetonitrile
was distilled from 4 A ˚ molecular sieves, and CH2Cl2 was distilled
from P2O5. All the above distillations were performed under a
nitrogen atmosphere. Triethylamine and pyridine were dried,
distilled, and kept over KOH. Other solvents and reagents were
used directly without any purification.
1H-NMR and
13C-NMR
spectra were collected by using Varian Inova-500 (500 MHz) and
Mercury Plus 400 (400 MHz) spectrometers (Figure S3). Abbre-
viations used in NMR analysis are as follows: s=singlet,
d=doublet, dd=double-doublet, ddd=double-double-doublet,
Figure 2. Effects of 1, 9, 12, 16, 32, 33, and 35 on phosphorylated and total proteins of Akt and ERK in A549 cells. A549 cells were
untreated or treated with 500 nM of 1, 9, 12, 16, 32, 33, and 35 for 24 h. Following 24 h of recovery, cell lysates were prepared and equal amounts of
protein were analyzed by SDS-PAGE. Immunoblots of cellular lysates were analyzed by antibodies of phosphorylated and total proteins of Akt and
ERK, with the expression of b-actin as an internal control. A. one of the selected immunoblot analysis results of pAkt, Akt, pERK, ERK and b-actin. B.
densitometric analysis results of pAkt, Akt, pERK, and ERK normalized to b-actin expression. Each histogram represents the mean values 6 standard
deviation of three dependent experiments. (*, p,0.05 compared with control; **, p,0.01 compared with control).
doi:10.1371/journal.pone.0030342.g002
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PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e30342Figure 3. Effects of 1, 9, 12, 16, 32, 33, and 35 on cyclins in A549 cells. A549 cells were untreated or treated with 500 nM of 1, 9, 12, 16, 32,
33, and 35 for 24 h. Following 24 h of recovery, cell lysates were prepared and equal amounts of protein were analyzed by SDS-PAGE. Immunoblots
of cellular lysates were analyzed by antibodies of CDK2, cyclin A, cyclin B1, cyclin D1, and cyclin E, with the expression of b-actin as an internal control.
A. one of the selected immunoblot analysis results of CDK2, CyclinA, CyclinB1, CyclinD1, CyclinE and b-actin. B. densitometric analysis results of CDK2,
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brdd=broad double-doublet. ESI-MS spectra were recorded with
Agilent LC/MSD TOF spectrometer. High-resolution mass
spectra were obtained with an AccuTOF-CS (JMS-T100CS,
JEOL) spectrometer. Optical rotations were collected on a Perkin-
Elmer 343 polarimeter. Purities of screening compounds were
assessed by HPLC [Xtimate C18, 4.66250 mm, 5 mm] (Figure S4).
All of the final products were purified by recrystallization with
chemical purities over 95% and ee vuales of these compounds were
determined by HPLC analysis on a chiral AD-H column
[CHIRALPAK AD-H, 4.66250 mm, 5 mm].
Stilbene acid (a)
The mixture of homoveratric acid (19.60 g, 0.10 mol), p-
anisaldehyde (12 mL, 0.10 mol), triethylamine (16 mL, 0.12 mol)
and acetic anhydride (24 mL, 0.12 mol) was heated to reflux for
10 h, then cooled, filtered, and the product was washed with small
portions of EtOAc to give yellow solid a (22.60 g, 72%). mp.207–
208uC.
1H-NMR (500 MHz, CDCl3): 7.88 (1H, s), 7.06 (2H, d,
J=8.5 Hz), 6.71 (2H, d, J=8.5 Hz), 6.76 (1H, brs), 6.81 (1H, brd,
J=8.0 Hz), 6.91 (1H, d, J=8.0 Hz), 3.92 (3H, s), 3.81 (3H, s),
3.77 (3H, s).
Esterification of Stilbene acid (b)
Acid a (17.60 g, 0.06 mol) was resolved in SOCl2 (15 mL,
0.08 mol) and the reaction mixture was refluxed for 30 min. After
evaporation of the solvent, pyridine (4.53 mL, 0.06 mol) was
added and then 30 mL of MeOH was added dropwise with
stirring in an ice bath for 30 min. The product b was obtained
after filtration and washed with small portions of MeOH. (14.73 g.
80%). mp 111–112uC.
1H-NMR (500 MHz, CDCl3): 7.77 (1H, s),
7.03 (2H, d, J=8.5 Hz), 6.69 (2H, d, J=8.5 Hz), 6.90 (1H, d,
J=8.0 Hz), 6.78 (1H, brd, J=8.0 Hz), 6.74 (1H, brs), 3.93 (3H,
s), 3.80 (3H, s), 3.79 (3H, s), 3.76 (3H, s).
Methyl 3, 6, 7-Trimethoxyphenanthrene-9-carboxylate (c)
To a solution of b (10.17 g, 0.03 mol) in CH2Cl2 was added
anhydrous FeCl3 (16.90 g, 0.11 mol) in one portion under an ice
bath. After being stirred for 12 h at room temperature, the
reaction was quenched with saturated NaHCO3 solvent and the
organic layer was collected after filtration and partition. Then the
organic layer was dried, evaporated and the product was
recrystallized from MeOH to give yellow globules. (4.50 g.
44%). mp 151–152uC.
1H-NMR (400 MHz, CDCl3): 8.61 (1H,
s), 8.37 (1H, s), 7.77 (1H, s), 7.71 (1H, d, J=2.5 Hz), 7.78 (1H, d,
J=9.0 Hz), 7.16 (1H, dd, J=9.0 Hz, 2.5 Hz), 4.07 (3H, s), 4.06
(3H, s), 3.99 (3H, s), 3.98 (3H, s).
9-(Hydroxymethyl)-3, 6, 7-trimethoxyphenanthren (d)
To a solution of LiAlH4 (1.00 g, 0.03 mol) in THF was added
the solution of c (4.25 g, 0.01 mol) at 0uC. After being stirred for
30 min at 20uC, the reaction was terminated with THF/H2O
(1:1). The mixture was filtered, dried, and then evaporated. And
the resulting white solid was recrystallized from MeOH to give
3.60 g product d as white needles with 93% yield. mp 155–156uC.
1H-NMR (400 MHz, CDCl3): 7.88 (1H, s), 7.58 (1H, s), 7.53 (1H,
s), 7.81 (1H, d, J=2.0 Hz), 7.75 (1H, d, J=9.0 Hz), 7.19 (1H, dd,
J=9.0 Hz, 2.0 Hz), 5.09 (2H, s), 4.10 (3H, s), 4.05 (3H, s), 4.01
(3H, s).
(S)-(+)-N-[(3, 6, 7-trimethoxy-9-phenanthryl)-
methyl]pyroglutamic acid (g)
To the solution of d (4.26 g, 0.01 mol) and NaI (4.25 g,
0.03 mol) in 250 mL of acetonitrile was added TMSCl (2.44 mL,
0.02 mol) with stirring at room temperature. e was precipitated in
10 min and then L-diisopropyl glutamate (6.56 g, 0.03 mol) and
K2CO3 (4.30 g, 0.03 mol) were added. After stirring for another
5 h, the suspension was evaporated, and the residue was
partitioned between water and CH2Cl2 (100 mL62). The organic
layer was separated, dried, and evaporated to give crude f as
brown oil. Then acetic acid (50 mL) and MeOH (100 mL) were
added to the resulting oil and the mixture was stirred at 50uC for
5 h. After evaporation, the resulting residue was dissolved in 1, 4-
dioxane (22 mL), MeOH (17 mL) and 2N KOH solution (11 mL,
0.02 mol). Upon completion of addition, the reaction mixture was
stirred at room temperature for 1 h, and evaporated, and the
residue was partitioned between water and CH2Cl2 (50 mL62).
The aqueous layer was acidified to pH 4 with H3PO4. The
product of g was filtered and recrystallized from MeOH as white
needles (3.10 g, 53% over four steps). mp 275–277uC.
1H-NMR
(400 MHz, CDCl3): 7.90 (1H, s), 7.84 (1H, d, J=2.0 Hz), 7.76
(1H, d, J=8.8 Hz), 7.61 (1H, s), 7.49 (1H, s), 7.19 (1H, dd,
J=8.8 Hz, 2.0 Hz), 5.61 (1H, d, J=14.4 Hz), 4.35 (1H, d,
J=14.4 Hz), 4.11 (3H, s), 4.04 (3H, s), 4.01 (3H, s), 3.87 (1H, m),
2.63 (1H, m), 2.42 (1H, m), 2.08–2.15 (2H, m).
(S)-3, 6, 7-trimethoxyphenanthro[9, 10-b]-11,
14-indolizidinedione (h)
To the solution of g (3.32 g, 0.01 mol) in trifluoroacetic
anhydride (10 mL, 0.07 mol) was added BF3?Et2O (20 mL,
0.16 mol) and the mixture was stirred for 3 h before poured into
50 mL of saturated NH4Cl solution. 200 mL of CH2Cl2 was
added to dissolve the resulting solid. The organic layer was
separated and washed with saturated NaHCO3 and H2O
sequentially, dried, evaporated, and washed with EtOAc to give
h as yellow powder (2.86 g, 90%). mp 249–251uC. [a]20 D +156
(c 1.0, CH2Cl2).
1H-NMR (400 MHz, CDCl3): 9.30 (1H, d,
J=9.2 Hz), 7.87 (1H, s), 7.77 (1H, d, J=2.4 Hz), 7.26 (1H, dd,
J=9.2 Hz, 2.4 Hz), 7.18 (1H, s), 5.6 (1H, d, J=18.0 Hz), 4.3 (1H,
d, J=18.0 Hz), 4.35 (1H, m), 4.13 (3H, s), 4.06 (3H, s), 4.01 (3H,
s), 2.50–2.59 (4H, m).
Table 3. The effects of 1, 9, 32 and 33 on cell cycle
distribution in A549 cells.
a
subG0/G1 (%) G0/G1 (%) S (%) G2/M (%)
control 1.53±0.22 59.95±0.21 31.25±0.78 8.80±0.42
1 (500 nM) 5.1864.41 54.1560.35
** 37.4060.14
** 8.4560.21
9 (500 nM) 3.8561.48 49.7565.59 45.8063.82
* 4.5061.84
32 (500 nM) 2.1460.25 47.0063.96
* 49.8063.25
* 3.2060.71
*
33 (500 nM) 1.9860.21 51.8060.14
** 42.8062.69
* 5.3562.76
aThese data indicate the percentage of cells in G0/G1,S ,a n dG 2/M phases of the
cell cycle. Each value is the mean 6 SD of three determinations. (*, p,0.05
compared with control; **, p,0.01 compared with control).
doi:10.1371/journal.pone.0030342.t003
CyclinA, CyclinB1, CyclinD1, and CyclinE normalized to b-actin expression. Each histogram represents the mean values 6 standard deviation of three
dependent experiments. (*, p,0.05 compared with control; **, p,0.01 compared with control).
doi:10.1371/journal.pone.0030342.g003
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indolizidinone (j)
To a solution of h (0.45 g, 1.13 mmol) in a mixture of CH2Cl2
(10 mL) and MeOH (10 mL) was added NaBH4 (0.10 g,
2.26 mmol). After stirring for 30 min, 20 mL of saturated NH4Cl
solution was poured into the reactant mixture with stirring. The
organic layer was separated, dried, and evaporated to give i. The
mixture of i,E t 3SiH (2 mL, 12.50 mmol) and BF3?Et2O (8 mL,
64.80 mmol) was intensively stirred for 6 h at room temperature.
10 mL of saturated NH4Cl solution was added slowly to quench
the reaction and then 20 mL of CH2Cl2 was added. The organic
layer was dried and evaporated. The residue was washed with hot
EtOH to give j (0.37 g, 85%). mp.216–218uC. [a]20 D +162 (c
0.2, CH2Cl2).
1H-NMR (500 MHz, CDCl3): 7.90 (1H, d,
J=9.0 Hz), 7.21 (1H, dd, J=9.0 Hz, 2.0 Hz), 7.88 (1H, d,
J=2.0 Hz), 7.90 (1H, s), 7.12 (1H, s), 5.25 (1H, d, J=17.0 Hz),
4.50 (1H, d, J=17.0 Hz), 4.11 (3H, s), 4.04 (3H, s), 4.02 (3H, s),
3.88 (1H, m), 3.51 (1H, m), 2.79 (1H, m), 2.52–2.59 (3H, m), 1.98
(1H, m).
(+)-13a-(S)-deoxytylophorinine (1)
To the solution of j (0.08 g, 0.21 mmol) in 10 mL of THF was
added LiAlH4 (0.01 g, 0.26 mmol) under the protection of argon
atmosphere. The mixture was heated to reflux and stirred for 2 h
in dark. Then the reaction mixture was cooled to room
temperature and added THF/H2O (1:1) dropwise to quench the
reaction, then filtered, dried, and evaporated. The product of 1
(0.06 g, 71%) was obtained by recrystallization from acetone/
MeOH (1:1) as white needles. mp.219–221uC. [a]20 D +102 (c
0.25, CHCl3). 99% ee [flow rate 1.0 mL/min, 18% isopropanol/
hexane and 0.2% Et3N, tR (major)=23.81 min, tR (min-
or)=31.22 min]. ESI-MS: 364.2 [M+H]
+.
1H-NMR (500 MHz,
CDCl3): d 7.92 (1H, d, J=9.0 Hz, H-1), 7.20 (1H, dd, J=9.0 Hz,
2.5 Hz, H-2), 7.87 (1H, d, J=2.5 Hz, H-4), 7.89 (1H, s, H-5), 7.12
(1H, s, H-8), 4.57 (1H, d, J=15.0 Hz, Ha-9), 3.61 (1H, d,
J=15.0 Hz, Hb-9), 4.09 (3H, s, CH3O-6), 4.04 (3H, s, CH3O-7),
4.00 (3H, s, CH3O-3), 3.46 (1H, m, Ha-11), 3.38 (1H, dd,
J=16.0 Hz, 2.5 Hz, Ha-14), 2.91 (1H, dd, J=16.0 Hz, 13.5 Hz,
Hb-14), 2.41–2.47 (2H, m, H-13a, Hb-11), 2.21 (1H, m, Ha-13),
2.02 (1H, m, Ha-12), 1.91 (1H, m, Hb-12), 1.75 (1H, m, Hb-13).
13C-NMR (125 MHz, CDCl3): d 157.52, 149.38, 148.23, 130.33,
126.97, 125.59, 125.54, 125.27, 125.10, 123.30, 114.74, 104.55,
103.95, 103.14, 60.13, 55.96, 55.88, 55.47, 55.13, 53.93, 33.55,
31.22, 21.59. HRESIMS calcd for [M+H]
+ C23H26NO3
364.1913, found 364.1925. The purity was 99.8% determined
by HPLC [flow rate 1.0 mL/min, 38% MeCN/H2O (0.06 M
NH4H2PO4, 0.2% Et3N, 2.5% THF)].
General Procedures for Synthesis of 2, 3, 4, 5, 6, 7
These derivatives were prepared from different substituted
phenanthrene-9-carboxylic ester and L- or D-glutamate. The
same reaction procedures and conditions were used as the
synthesis of (+)-deoxytylophorinine.
(2)-13a-(R)-deoxytylophorinine (2)
7% total yield. White needles (from acetone/MeOH (1:1)). mp
219–221uC. [a]20 D 2114 (c 0.25, CHCl3). 99% ee [flow rate
1.0 mL/min, 18% isopropanol/hexane and 0.2% Et3N, tR
(major)=31.30 min, tR (minor)=24.00 min]. ESI-MS: 364.2
(M+H)
+.
1H-NMR (400 MHz, CDCl3): d 7.92 (1H, d,
J=9.2 Hz, H-1), 7.21 (1H, dd, J=9.2 Hz, 2.0 Hz, H-2), 7.88
(1H, d, J=2.0 Hz, H-4), 7.90 (1H, s, H-5), 7.12 (1H, s, H-8), 4.62
(1H, d, J=14.8 Hz, Ha-9), 3.71 (1H, d, J=14.8 Hz, Hb-9), 4.09
(3H, s, CH3O-6), 4.04 (3H, s CH3O-7), 4.00 (3H, s, CH3O-3),
3.45 (1H, m, Ha-11), 3.41 (1H, dd, J=16.0 Hz, 2.8 Hz, Ha-14),
2.98 (1H, dd, J=16.0 Hz, 10.8 Hz, Hb 214), 2.52–2.61 (2H, m,
H-13a, Hb-11), 2.25 (1H, m, Ha-13), 2.05 (1H, m, Ha-12), 1.94
(1H, m, Hb-12), 1.80 (1H, m, Hb-13).
13C-NMR (100 MHz,
CDCl3): d 157.61, 149.42, 148.30, 130.39, 126.78, 125.42, 125.41,
125.21, 125.11, 123.34, 114.83, 104.55, 103.92, 103.02, 60.15,
55.96, 55.90, 55.48, 54.91, 53.46, 33.03, 31.03, 21.53. HRESIMS
calcd for [M+H]
+ C23H26NO3 364.1913, found 364.1920. HPLC
purity: 99.9% [flow rate 1.0 mL/min, 38% MeCN/H2O (0.06 M
NH4H2PO4, 0.2% Et3N, 2.5% THF)].
(S)-2, 3, 6, 7-tetramethoxyphenanthro[9, 10-b]-
indolizidine [(+)-Tylophorine] (3)
7% total yield. White needles (from acetone/MeOH (1:1)). mp
284–286uC. [a]20 D +73 (c 0.1, CH2Cl2). 93% ee [flow rate
1.0 mL/min, 26% isopropanol/hexane and 0.2% Et3N, tR
(major)=10.28 min, tR (minor)=13.16 min].
1H-NMR
(500 MHz, CDCl3): d 7.82 (2H, brs), 7.31 (1H, s), 7.15 (1H, s),
4.11 (6H, s), 4.06 (3H, s), 4.05 (3H, s), 4.63 (1H, d, J=14.5 Hz),
3.66 (1H, d, J=14.5 Hz), 3.48 (1H, brs), 3.37 (1H, brd,
J=16.0 Hz), 2.93 (1H, d, J=16.0 Hz, 10.5 Hz), 2.47–2.50 (2H,
m), 2.23 (1H, m), 2.05 (1H, m), 1.94 (1H, m), 1.79 (1H, m).
HRESIMS calcd for [M+H]
+ C24H28NO4 394.2013, found
394.2026. HPLC purity: 98.6% [flow rate 1.0 mL/min, 46%
MeCN/H2O (0.08 M NH4H2PO4, 0.2% Et3N)].
(S)-2, 3, 6-trimethoxyphenanthro[9, 10-b]-indolizidine
[(+)-Antofine] (4)
6% total yield. White needles (from acetone). mp 215–217uC.
[a]20 D +102 (c 0.1, CH2Cl2). 97% ee [flow rate 1.0 mL/min,
26% isopropanol/hexane and 0.2% Et3N, tR (major)=14.49 min,
tR (minor)=21.27 min].
1H-NMR (500 MHz, CDCl3): d 7.91
(1H, s), 7.90 (1H, d, J=2.0 Hz), 7.80 (1H, d, J=9.0 Hz), 7.20
(1H, dd, J=9.0 Hz, 2.0 Hz), 7.30 (1H, s), 4.70 (1H, d,
J=15.0 Hz), 3.70 (1H, d, J=15.0 Hz), 4.10 (3H, s), 4.06 (3H,
s), 4.01 (3H, s), 3.47 (1H, brs), 3.34 (1H, brd, J=15.5 Hz), 2.91
(1H, dd, J=15.5 Hz, 10.5 Hz), 2.44–2.53 (2H, m), 2.24 (1H, m),
2.04 (1H, m), 1.93 (1H, m), 1.79 (1H, m). HRESIMS calcd for
[M+H]
+ C23H26NO3 364.1907, found 364.1918. HPLC purity:
99.1% [flow rate 1.0 mL/min, 46% MeCN/H2O (0.08 M
NH4H2PO4, 0.2% Et3N)].
(S)-2, 6, 7-trimethoxyphenanthro[9, 10-b]-indolizidine (5)
5% total yield. White solid (from acetone). mp 198–200uC.
[a]20 D +97 (c 0.1, CH2Cl2). 100% ee [flow rate 1.0 mL/min,
26% isopropanol/hexane and 0.2% Et3N, tR=25.08 min].
1H-
NMR (400 MHz, CDCl3): d 8.43 (1H, d, J=9.2 Hz), 7.21 (1H,
dd, J=9.2 Hz, 2.8 Hz), 7.31 (1H, d, J=2.8 Hz), 7.90 (1H, s), 7.12
(1H, s), 4.59 (1H, d, J=14.8 Hz), 3.61 (1H, d, J=14.8 Hz), 4.08
(3H, s), 4.03 (3H, s), 3.96 (3H, s), 3.46 (1H, m), 3.31 (1H, dd,
J=15.6 Hz, 2.8 Hz), 2.87 (1H, dd, J=15.6 Hz, 10.4 Hz), 2.39–
2.46 (2H, m), 2.21 (1H, m), 2.02 (1H, m), 1.91 (1H, m), 1.75 (1H,
m). HRESIMS calcd for [M+H]
+ C23H26NO3 364.1907, found
364.1916. HPLC purity: 99.2% [flow rate 1.0 mL/min, 46%
MeCN/H2O (0.08 M NH4H2PO4, 0.2% Et3N)].
(S)-3-fluoro-6, 7-dimethoxyphenanthro[9, 10-b]-
indolizidine (6)
9% total yield. Light yellow solid (from acetone/MeOH (1:1)).
mp 190–192uC. [a]20 D +92 (c 0.1, CH2Cl2). 92% ee [flow rate
1.0 mL/min, 26% isopropanol/hexane and 0.2% Et3N, tR
(major)=9.29 min, tR (minor)=13.24 min].
1H-NMR (500 MHz,
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6.0 Hz), 7.29 (1H, ddd, J=9.0 Hz, 8.5 Hz, 2.0 Hz), 7.85 (1H, s),
7.16 (1H, s), 4.60 (1H, d, J=15.0 Hz), 3.66 (1H, d, J=15.0 Hz),
4.10 (3H, s), 4.06 (3H, s), 3.47 (1H, m), 3.41 (1H, brd,
J=16.0 Hz), 2.95 (1H, dd, J=16.0 Hz, 10.5 Hz), 2.45–2.48
(2H, m), 2.24 (1H, m), 2.03 (1H, m), 1.93 (1H, m), 1.76 (1H, m).
HRESIMS calcd for [M+H]
+ C22H23FNO2 352.1707, found
352.1719. HPLC purity: 98.4% [flow rate 1.0 mL/min, 46%
MeCN/H2O (0.08 M NH4H2PO4, 0.2% Et3N)].
(S)- 6, 7-dimethoxyphenanthro[9, 10-b]-indolizidine (7)
8% total yield. White solid (from acetone/MeOH (1:1)). mp 196–
198uC. [a]20 D +112 (c 0.1, CH2Cl2). 90% ee [flow rate 1.0 mL/
min, 26% isopropanol/hexane and 0.2% Et3N, tR (major)=13.70 -
min, tR (minor)=24.50 min].
1H-NMR (400 MHz, CDCl3): d 8.53
(1H, d, J=7.6 Hz), 8.03 (1H, s), 8.01 (H, d, J=7.6 Hz), 7.57 (2H,
brdd, J=7.6 Hz, 7.6 Hz), 7.16 (1H, s), 4.62 (1H, d, J=14.8 Hz),
3.66 (1H, d, J=14.8 Hz), 4.10 (3H, s), 4.05 (3H, s), 3.43–3.49 (2H,
m), 2.97 (1H, dd, J=15.6 Hz, 10.8 Hz), 2.43–2.49 (2H, m), 2.23
(1H, m), 2.03 (1H, m), 1.92 (1H, m), 1.77 (1H, m). HRESIMS calcd
for [M+H]
+ C22H24NO2 334.1802, found 334.1808. HPLC purity:
99.9% [flow rate 1.0 mL/min, 46% MeCN/H2O (0.08 M
NH4H2PO4, 0.2% Et3N)].
(13aS,1 4 R)-14-methoxy-3, 6, 7-trimethoxyphenanthro[9,
10-b]-11-indolizidinone (k) and (13aS,1 4 S)-14-methoxy-3,
6, 7-trimethoxyphenanthro[9, 10-b] -11-indolizidinone (l)
To the solution of i (0.20 g, 0.51 mmol) in 5 mL of THF was
added NaH (70%, 0.07 g, 2.04 mmol) under protection of
nitrogen gas. The mixture was stirred at room temperature for
30 min and then CH3I (0.16 mL, 3.15 mmol) was added. The
reaction was continued for another 5 h and quenched by 10 mL of
saturated NH4Cl solution. The organic layer was washed with
water and dried. After evaporation the residue was isolated by
silica gel column chromatography eluting with CH2Cl2/MeOH
(50:1) to give k (0.06 g, 29%)and l (0.08 g, 39%) respectively.
k.
1H-NMR (500 MHz, CDCl3): d 8.21 (1H, d, J=9.0 Hz),
7.22 (1H, dd, J=9.0 Hz, 2.0 Hz), 7.88 (1H, d, J=2.0 Hz), 7.91
(1H, s), 7.21 (1H, s), 5.38 (1H, d, J=17.0 Hz), 4.43 (1H, d,
J=17.0 Hz), 5.15 (1H, d, J=7.0 Hz), 4.07 (1H, m), 4.12 (3H, s),
4.06 (3H, s), 4.02 (3H, s), 3.19 (3H, s), 2.66 (1H, m), 2.58 (2H, m),
2.24 (1H, m). NOEs were observed between H-14 (dH 5.15) and
H-13 (dH 2.23), CH3O-14 (dH 3.19), and H-1 (dH 8.21).
l.
1H-NMR (500 MHz, CDCl3): d 8.19 (1H, d, J=9.0 Hz),
7.27 (1H, dd, J=9.0 Hz, 2.0 Hz), 7.92 (1H, d, J=2.0 Hz), 7.93
(1H, s), 7.26 (1H, s), 5.36 (1H, d, J=17.5 Hz), 4.63 (1H, d,
J=17.5 Hz), 5.19 (1H, brs), 3.96 (1H, m), 4.12 (3H, s), 4.06 (3H,
s), 4.02 (3H, s), 3.16 (3H, s), 2.68 (1H, m), 2.60–2.51 (2H, m), 2.32
(1H, m). NOEs were observed between H-14 (dH 5.19) and
CH3O-14 (dH 3.16), H-13a (dH 3.96), and H-1 (dH 8.19).
(13aS,1 4 R)-14-methoxy-3, 6, 7-trimethoxyphenanthro[9,
10-b]-indolizidine (8)
To the solution of k (0.08 g, 0.20 mmol) in 5 mL of THF was
added LiAlH4 (0.04 g, 1.05 mmol) under nitrogen gas. The
mixture was heated to reflux and continued for 2 h in dark and
then cooled to room temperature. THF/H2O (1:1) was added
slowly to the reactant until no bubble evolved. The mixture was
filtered and the filtrate was dried and evaporated. The residue was
recrystallized from MeOH to gave 8 (0.06 g, 78%) as white solid.
mp 208–210uC (decomposed). [a]20 D +88 (c 0.1, CH2Cl2). 92%
ee [flow rate 1.0 mL/min, 8% isopropanol/hexane and 0.2%
Et3N, tR (major)=10.32 min, tR (minor)=18.27 min].
1H-NMR
(500 MHz, C5D5N): d 8.50 (1H, d, J=9.0 Hz), 7.42 (1H, brd,
J=9.0 Hz), 8.33 (2H, brs), 7.44 (1H, s), 5.26 (1H, d, J=8.0 Hz),
4.68 (1H, d, J=14.5 Hz), 3.71 (1H, d, J=14.5 Hz), 3.98 (3H, s),
3.94 (3H, s), 3.90 (3H, s), 3.34 (3H, s), 3.25 (1H, brt, J=7.5 Hz),
2.68 (1H, m), 2.38–2.33 (2H, m), 1.94–1.84 (2H, m), 1.76 (1H, m).
13C-NMR (125 MHz, C5D5N): d 158.24, 150.57, 150.10
(overlapped), 131.62, 130.03, 128.53, 128.31, 125.68 (62),
124.95, 115.74, 105.22, 104.99, 104.85, 81.00, 64.85, 56.00,
55.82, 55.41, 54.61, 54.22, 54.11, 31.77, 22.45. HRESIMS calcd
for [M+H]
+ C24H28NO4 394.2013, found 394.2024. HPLC
purity: 99.9% [flow rate 1.0 mL/min, 46% MeCN/H2O
(0.08 M NH4H2PO4, 0.2% Et3N)].
(13aS,1 4 S)-14-methoxy-3, 6, 7-trimethoxyphenanthro[9,
10-b]-indolizidine (9)
The same reaction procedures and conditions were involved as
the synthesis of 8. 69% yield. White globules (from MeOH). mp
173–175uC. [a]20 D +73 (c 0.1, CH2Cl2). 100% ee [flow rate
1.0 mL/min, 26% isopropanol/hexane and 0.2% Et3N,
tR=17.57 min].
1H-NMR (500 MHz, C5D5N): d 8.63 (1H, d,
J=9.0 Hz), 7.46 (1H, brd, J=9.0 Hz), 8.38 (2H, brs), 7.49 (1H,
s), 5.28 (1H, brs), 4.86 (1H, d, J=15.0 Hz), 3.54 (1H, d,
J=15.0 Hz), 4.01 (3H, s), 3.96 (3H, s), 3.92 (3H, s), 3.45 (3H,
s), 3.33 (1H, brt, J=7.5 Hz), 2.45–2.49 (2H, m), 2.21 (1H, m),
1.90–1.93 (2H, m), 1.74 (1H, m).
13C-NMR (125 MHz, C5D5N): d
158.54, 150.59, 150.10 (overlapped), 131.43, 130.16, 127.18,
126.42, 125.74, 125.44, 125.32, 116.21, 105.25, 104.94 (62),
71.10, 65.70, 56.03, 55.85, 55.48 (62), 54.57, 54.41, 24.67, 22.13.
HRESIMS calcd for [M+H]
+ C24H28NO4 394.2013, found
394.2024. HPLC purity: 99.9% [flow rate 1.0 mL/min, 46%
MeCN/H2O (0.08 M NH4H2PO4, 0.2% Et3N)].
(13aR,1 4 S)-14-methoxy-3, 6, 7-trimethoxyphenanthro[9,
10-b]-indolizidine (10)
The same reaction procedures and conditions were involved as
the synthesis of 8. 66% yield. White solid (from MeOH). mp 208–
210uC (decomposed). [a]20 D 286 (c 0.1, CH2Cl2). 99% ee [flow
rate 1.0 mL/min, 8% isopropanol/hexane and 0.2% Et3N, tR
(major)=18.38 min, tR (minor)=10.35 min].
1H-NMR
(500 MHz, C5D5N): d 8.50 (1H, d, J=9.0 Hz), 7.42 (1H, brd,
J=9.0 Hz), 8.33 (2H, brs), 7.43 (1H, s), 5.26 (1H, d, J=8.0 Hz),
4.68 (1H, d, J=14.5 Hz), 3.71 (1H, d, J=14.5 Hz), 3.98 (3H, s),
3.94 (3H, s), 3.90 (3H, s), 3.34 (3H, s), 3.25 (1H, brt, J=8.0 Hz),
2.69 (1H, m), 2.33–2.37 (2H, m), 1.84–1.94 (2H, m), 1.76 (1H, m).
HRESIMS calcd for [M+H]
+ C24H28NO4 394.2013, found
394.2020. HPLC purity: 99.9% [flow rate 1.0 mL/min, 46%
MeCN/H2O (0.08 M NH4H2PO4, 0.2% Et3N)].
(13aR,1 4 R)-14-methoxy-3, 6, 7-trimethoxyphenanthro[9,
10-b]-indolizidine (11)
The same reaction procedures and conditions were involved as the
synthesis of 8. 72% yield. White globules (from MeOH). mp 173–
175uC. [a]20 D 277 (c 0.1, CH2Cl2). 94% ee [flow rate 1.0 mL/min,
26% isopropanol/hexane and 0.2% Et3N, tR (major)=23.34 min, tR
(minor)=18.16 min].
1H-NMR (500 MHz, C5D5N): d 8.63 (1H, d,
J=9.0 Hz), 7.46 (1H, dd, J=9.0 Hz,2.5 Hz),8.39 (1H,s),8.38(1H,
d, 2.5 Hz),7.50 (1H, s), 5.29 (1H,brs),4.86 (1H,d, J=15.0 Hz),3.54
(1H, d, J=15.0 Hz), 4.01 (3H, s), 3.96 (3H, s), 3.92 (3H, s), 3.45 (3H,
s), 3.33 (1H, brt, J=7.5 Hz), 2.45–2.50 (2H, m), 2.21 (1H, m), 1.90–
1.93 (2H, m), 1.75 (1H, m). HRESIMS calcd for [M+H]
+
C24H28NO4 394.2013, found 394.2021. HPLC purity: 99.6% [flow
rate 1.0 mL/min, 46% MeCN/H2O (0.08 M NH4H2PO4, 0.2%
Et3N)].
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The solution of h (0.50 mmol) in 10 mL of dry CH2Cl2 was
cooled to 220uC. To this solution was added amine (0.1 mL) and
TiCl4 (0.25 mmol) sequently under nitrogen gas. The mixture was
stirred and warmed slowly to room temperature in 2 h. The
reaction was continued for another 24 h and filtered. The filtrate
was concentrated to 5 mL and added 5 mL of MeOH. NaBH4
(0.10 g) was added to the resulting solution and stirred for 30 min,
then quenched with saturated NH4Cl solution. The organic layer
was dried and evaporated. The residue was subjected to silica gel
column chromatography eluting by CH2Cl2/MeOH (50:1) to give
m and n respectively. Reduction of m and n by LiAlH4 afforded
target compounds. These compounds could be purified by
recrystallization from MeOH or acetone/H2O (1:1) mixture
respectively.
(13aS,1 4 R)-14-benzylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-11-indolizidinone (m)
58% yield. White solid (from MeOH).
1H-NMR (500 MHz,
CDCl3): d 8.01 (1H, d, J=9.0 Hz), 7.88 (1H, m), 7.89 (1H, s),
7.28–7.17 (7H, m), 5.45 (1H, d, J=16.5 Hz), 4.37 (1H, d,
J=16.5 Hz), 4.55 (1H, d, J=6.5 Hz), 4.09 (1H, overlapped), 4.11
(3H, s), 4.06 (3H, s), 4.02 (3H, s), 3.77 (1H, d, J=12.5 Hz), 3.63
(1H, d, J=12.5 Hz) 2.70 (1H, m), 2.56–2.60 (2H, m), 2.18 (1H,
m).
(13aS,1 4 S)-14-benzylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-11-indolizidinone (n)
39% yield. White solid (from MeOH).
1H-NMR (500 MHz,
CDCl3): d 8.05 (1H, d, J=9.5 Hz), 7.93 (2H, s), 7.28–7.19 (7H,
m), 5.34 (1H, d, J=18.0 Hz), 4.65 (1H, d, J=18.0 Hz), 4.53 (1H,
brs), 3.99 (1H, m), 4.12 (3H, s), 4.06 (3H, s), 4.05 (3H, s), 3.91 (1H,
d, J=12.5 Hz), 3.82 (1H, d, J=12.5 Hz) 2.80 (1H, m), 2.55–2.61
(2H, m), 2.31 (1H, m).
(13aS,1 4 R)-14-benzylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-indolizidine (12)
82% yield. Light yellow cluster crystals (from MeOH). mp 192–
194uC. [a]20 D +33 (c 0.1, CH2Cl2). 100% ee [flow rate 1.0 mL/
min, 1% isopropanol/hexane and 0.2% Et3N, tR=67.62 min].
1H-NMR (500 MHz, C5D5N): d 8.67 (1H, d, J=9.0 Hz), 7.43
(1H, dd, J=9.0 Hz, 2.0 Hz), 8.33 (1H, d, J=2.0 Hz), 8.35 (1H,
s), 7.48 (1H, s), 7.47 (2H, d, J=8.5 Hz), 7.30 (2H, t, J=8.5 Hz),
7.22 (1H, t, J=8.5 Hz), 4.73 (1H, d, J=6.5 Hz), 4.70 (1H, d,
J=15.0 Hz), 3.76 (1H, d, J=15.0 Hz), 3.98 (3H, s), 3.95 (3H, s),
3.90 (3H, s), 3.97 (1H, overlapped), 3.82 (1H, d, J=12.5 Hz), 3.30
(1H, brt, J=7.0 Hz), 2.70 (1H, m), 2.37–2.45 (2H, m), 1.88–1.92
(2H, m), 1.79 (1H, m).
13C-NMR (125 MHz, C5D5N): d 158.17,
150.60, 150.10 (overlapped), 142.06, 131.84, 130.51, 129.34 (64),
128.57, 128.36, 127.04, 126.07, 125.58, 124.59, 115.40, 105.31,
104.88 (62), 68.07, 61.09, 56.06, 55.85, 55.40, 54.79, 54.17,
50.77, 32.29, 22.50. HRESIMS calcd for [M+H]
+ C30H33N2O3
469.2486, found 469.2502. HPLC purity: 98.2% [flow rate
1.0 mL/min, 46% MeCN/H2O (0.08 M NH4H2PO4, 0.2%
Et3N)].
(13aS,1 4 S)-14-benzylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-indolizidine (13)
84% yield. Light yellow cluster crystals (from MeOH). mp 147–
149uC. [a]20 D +46 (c 0.1, CH2Cl2). 100% ee [flow rate 1.0 mL/
min, 26% isopropanol/hexane and 0.2% Et3N, tR=13.96 min].
1H-NMR (500 MHz, C5D5N): d 8.51 (1H, d, J=9.0 Hz), 7.46
(1H, dd, overlapped), 8.39 (2H, brs), 7.47 (1H, s), 7.44 (2H, d,
J=7.5 Hz), 7.28 (2H, t, J=7.5 Hz), 7.21 (1H, t, overlapped), 4.85
(1H, d, J=15.0 Hz), 3.70 (1H, d, J=15.0 Hz), 4.63 (1H, brs),
4.27 (1H, d, J=14.0 Hz), 4.04 (1H, d, J=14.0 Hz), 4.00 (3H, s),
3.94 (3H, s), 3.93 (3H, s), 3.37 (1H, brt, J=7.5 Hz), 2.66 (1H, m),
2.46–2.54 (2H, m), 2.34 (1H, m), 1.85–1.96 (2H, m), 1.78 (1H, m).
13C-NMR (125 MHz, C5D5N): d 158.34, 150.60, 150.10
(overlapped), 142.79, 131.53, 131.28, 128.51 (62), 128.43 (62),
127.17, 126.95, 126.87, 126.26, 125.99, 124.73, 115.75, 105.33,
104.98, 104.75, 65.62, 56.06, 55.84, 55.61, 55.47, 54.71, 53.24,
52.61, 26.07, 22.65. HRESIMS calcd for [M+Na]
+
C30H32N2NaO3 491.2311, found 491.2243. HPLC purity:
98.7% [flow rate 1.0 mL/min, 46% MeCN/H2O (0.08 M
NH4H2PO4, 0.2% Et3N)].
(13aR,1 4 S)-14-benzylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-indolizidine (14)
79% yield. Light yellow cluster crystals (from MeOH). mp 192–
194uC. [a]20 D 232 (c 0.1, CH2Cl2). 100% ee [flow rate 1.0 mL/
min, 1% isopropanol/hexane and 0.2% Et3N, tR=62.37 min].
1H-NMR (500 MHz, C5D5N): d 8.67 (1H, d, J=9.0 Hz), 7.43
(1H, brd, J=9.0 Hz), 8.33 (1H, brs), 8.35 (1H, s), 8.48 (1H, s),7.47
(2H, d, J=7.5 Hz), 7.30 (2H, t, J=7.5 Hz), 7.22 (1H, t,
J=7.5 Hz), 4.73 (1H, d, J=7.0 Hz), 4.70 (1H, d, J=14.5 Hz),
3.76 (1H, d, J=14.5 Hz), 3.98 (3H, s), 3.95 (3H, s), 3.90 (3H, s),
3.97 (1H, overlapped), 3.82 (1H, d, J=13.0 Hz), 3.30 (1H, brt,
J=7.5 Hz), 2.70 (1H, m), 2.37–2.45 (2H, m), 1.88–1.92 (2H, m),
1.81 (1H, m). HRESIMS calcd for [M+H]
+ C30H33N2O3
469.2486, found 469.2498. HPLC purity: 99.0% [flow rate
1.0 mL/min, 46% MeCN/H2O (0.08 M NH4H2PO4, 0.2%
Et3N)].
(13aR,1 4 R)-14-benzylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-indolizidine (15)
80% yield. Light yellow cluster crystals (from MeOH). mp 147–
149uC. [a]20 D 247 (c 0.1, CH2Cl2). 100% ee [flow rate 1.0 mL/
min, 26% isopropanol/hexane and 0.2% Et3N, tR=16.62 min].
1H-NMR (500 MHz, C5D5N): d 8.51 (1H, d, J=9.0 Hz), 7.45
(1H, dd, overlapped), 8.40 (2H, brs), 7.48 (1H, s), 7.44 (2H, d,
J=7.5 Hz), 7.27 (2H, t, J=7.5 Hz), 7.21 (1H, overlapped), 4.86
(1H, d, J=15.0 Hz), 3.70 (1H, d, J=15.0 Hz), 4.63 (1H, brs),
4.27 (1H, d, J=14.0 Hz), 4.04 (1H, d, J=14.0 Hz), 4.00 (3H, s),
3.94 (3H, s), 3.93 (3H, s), 3.37 (1H, brt, J=7.5 Hz), 2.69 (1H, m),
2.46–2.54 (2H, m), 2.33 (1H, m), 1.85–1.96 (2H, m), 1.77 (1H, m).
HRESIMS calcd for [M+H]
+ C30H33N2O3 469.2486, found
469.2502. HPLC purity: 99.8% [flow rate 1.0 mL/min, 46%
MeCN/H2O (0.08 M NH4H2PO4, 0.2% Et3N)].
(13aS,1 4 R)-14-propylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-indolizidine (16)
69% yield. Light yellow needles (from MeOH). mp 129–131uC.
[a]20 D +50 (c 0.1, CH2Cl2). 98% ee [flow rate 1.0 mL/min, 8%
isopropanol/hexane and 0.2% Et3N, tR (major)=9.34 min, tR
(minor)=17.18 min].
1H-NMR (500 MHz, C5D5N): d 8.59 (1H,
d, J=9.0 Hz), 7.44 (1H, dd, J=9.0 Hz, 2.0 Hz), 8.33 (1H, d,
J=2.0 Hz), 8.34 (1H, s), 7.46 (1H, s), 4.69 (1H, d, J=15.0 Hz),
3.71 (1H, d, J=15.0 Hz), 4.55 (1H, d, J=7.0 Hz), 3.98 (3H, s),
3.95 (3H, s), 3.91 (3H, s), 3.29 (1H, brt, J=7.5 Hz), 2.69 (1H, m),
2.56–2.62 (2H, m), 2.34–2.39 (2H, m), 1.85–1.89 (2H, m), 1.77–
1.79 (2H, m), 1.39–1.44 (2H, m), 0.83 (3H, t, J=7.5 Hz).
13C-
NMR (125 MHz, C5D5N): d 158.13, 150.60, 150.10 (overlapped),
131.83, 130.99, 129.04, 128.35, 126.11, 125.69, 124.51, 115.33,
105.32, 104.90 (62), 68.49, 61.32, 56.05, 55.85, 55.41, 54.77,
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[M+H]
+ C26H33N2O3 421.2485, found 421.2489. HPLC purity:
99.6% [flow rate 1.0 mL/min, 46% MeCN/H2O (0.08 M
NH4H2PO4, 0.2% Et3N)].
(13aS,1 4 S)-14-propylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-indolizidine (17)
65% yield. Light yellow cluster crystals (from acetone/H2O
(1:1)). mp 137–139uC. [a]20 D +68 (c 0.1, CH2Cl2). 98% ee [flow
rate 1.0 mL/min, 8% isopropanol/hexane and 0.2% Et3N, tR
(major)=20.37 min, tR (minor)=38.33 min].
1H-NMR
(500 MHz, C5D5N): d 8.51 (1H, d, J=9.0 Hz), 7.51 (1H, dd,
J=9.0 Hz, 2.5 Hz), 8.38 (1H, d, J=2.5 Hz), 8.37 (1H, s), 7.46
(1H, s), 4.86 (1H, d, J=15.0 Hz), 3.67 (1H, d, J=15.0 Hz), 4.47
(1H, brs), 3.99 (3H, s), 3.94 (3H, s), 3.93 (3H, s), 3.38 (1H, brt,
J=7.5 Hz), 3.03 (1H, m), 2.87 (1H, m), 2.64 (1H, m), 2.31–2.40
(2H, m), 1.86–1.95 (2H, m), 1.76 (1H, m), 1.41–1.45 (2H, m), 0.81
(3H, t, J=7.5 Hz).
13C-NMR (125 MHz, C5D5N): d 158.29,
150.57, 150.10 (overlapped), 131.93, 131.55, 127.11, 126.45,
126.29, 126.00, 124.62, 115.70, 105.33, 105.01, 104.73, 65.67,
56.04, 55.82, 55.62, 55.47, 54.76, 53.86, 51.41, 26.06, 24.89,
22.57, 12.13. HRESIMS calcd for [M+Na]
+ C26H32N2NaO3
443.2311, found 443.2308. HPLC purity: 99.8% [flow rate
1.0 mL/min, 46% MeCN/H2O (0.08 M NH4H2PO4, 0.2%
Et3N)].
(13aR,1 4 S)-14-propylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-indolizidine (18)
71% yield. Light yellow needles (from MeOH). mp 129–131uC.
[a]20 D 250 (c 0.1, CH2Cl2). 100% ee [flow rate 1.0 mL/min, 8%
isopropanol/hexane and 0.2% Et3N, tR=17.43 min].
1H-NMR
(500 MHz, C5D5N): d 8.59 (1H, d, J=9.0 Hz), 7.44 (1H, dd,
J=9.0 Hz, 2.0 Hz), 8.33 (1H, d, J=2.0 Hz), 8.34 (1H, s), 7.46
(1H, s), 4.68 (1H, d, J=15.0 Hz), 3.72 (1H, d, J=15.0 Hz), 4.55
(1H, d, J=7.0 Hz), 3.98 (3H, s), 3.95 (3H, s), 3.91 (3H, s), 3.28
(1H, brt, J=7.5 Hz), 2.69 (1H, m), 2.56–2.62 (2H, m), 2.34–2.39
(2H, m), 1.85–1.89 (2H, m), 1.78 (1H, m), 1.40–1.44 (2H, m), 0.83
(3H, t, J=7.5 Hz). HRESIMS calcd for [M+H]
+ C26H33N2O3
421.2486, found 421.2494. HPLC purity: 99.1% [flow rate
1.0 mL/min, 46% MeCN/H2O (0.08 M NH4H2PO4, 0.2%
Et3N)].
(13aR,1 4 R)-14-propylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-indolizidine (19)
66% yield. Light yellow cluster crystals (from acetone/H2O
(1:1)). mp 137–139uC. [a]20 D 268 (c 0.1, CH2Cl2). 99% ee [flow
rate 1.0 mL/min, 8% isopropanol/hexane and 0.2% Et3N, tR
(major)=38.29 min, tR (minor)=20.97 min].
1H-NMR
(500 MHz, C5D5N): d 8.51 (1H, d, J=9.0 Hz), 7.51 (1H, dd,
J=9.0 Hz, 2.5 Hz), 8.38 (1H, d, J=2.5 Hz), 8.37 (1H, s), 7.46
(1H, s), 4.86 (1H, d, J=15.0 Hz), 3.67 (1H, d, J=15.0 Hz), 4.47
(1H, brs), 3.99 (3H, s), 3.94 (3H, s), 3.93 (3H, s), 3.38 (1H, brt,
J=8.0 Hz), 3.03 (1H, m), 2.86 (1H, m), 2.63 (1H, m), 2.31–2.40
(2H, m), 1.86–1.95 (2H, m), 1.78 (1H, m), 1.39–1.46 (2H, m), 0.81
(3H, t, J=7.5 Hz). HRESIMS calcd for [M+H]
+ C26H32N2NaO3
421.2486, found 421.2489. HPLC purity: 99.5% [flow rate
1.0 mL/min, 46% MeCN/H2O (0.08 M NH4H2PO4, 0.2%
Et3N)].
(13aS,1 4 R)-14-isopropylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-indolizidine (20)
83% yield. White solid (from MeOH). mp 117–119uC. [a]20 D
+47 (c 0.1, CH2Cl2). 98% ee [flow rate 1.0 mL/min, 8%
isopropanol/hexane and 0.2% Et3N, tR (major)=7.58 min, tR
(minor)=6.55 min].
1H-NMR (500 MHz, C5D5N): d 8.69 (1H, d,
J=9.0 Hz), 7.45 (1H, dd, J=9.0 Hz, 2.0 Hz), 8.33 (1H, d,
J=2.0 Hz), 8.34 (1H, s), 7.46 (1H, s), 4.75 (1H, d, J=7.0 Hz),
4.65 (1H, d, J=14.5 Hz), 3.69 (1H, d, J=14.5 Hz), 3.98 (3H, s),
3.95 (3H, s), 3.90 (3H, s), 3.16–3.25 (2H, m), 2.51 (1H, m), 2.31–
2.39 (2H, m), 1.74–1.92 (3H, m), 1.27 (3H, d, J=6.0 Hz), 0.96
(3H, d, J=6.0 Hz).
13C-NMR (125 MHz, C5D5N): d 158.02,
150.57, 150.10 (overlapped), 131.85, 131.31, 128.99, 128.85,
126.17, 125.77, 124.48, 115.11, 105.27, 104.87, 104.76, 70.00,
57.66, 56.03, 55.85, 55.42, 54.40, 53.61, 45.74, 32.96, 25.30,
22.59, 22.19. HRESIMS calcd for [M+H]
+ C26H33N2O3
421.2486, found 421.2496. HPLC purity: 97.7% [flow rate
1.0 mL/min, 46% MeCN/H2O (0.08 M NH4H2PO4, 0.2%
Et3N)].
(13aS,1 4 S)-14-isopropylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-indolizidine (21)
71% yield. Light yellow amorphous solid (from acetone/H2O
(1:1)). mp 149–151uC. [a]20 D +65 (c 0.1, CH2Cl2). 100% ee [flow
rate 1.0 mL/min, 8% isopropanol/hexane and 0.2% Et3N,
tR=17.34 min].
1H-NMR (500 MHz, C5D5N): d 8.58 (1H, d,
J=9.0 Hz), 7.51 (1H, dd, J=9.0 Hz, 2.0 Hz), 8.38 (1H, d,
J=2.0 Hz), 8.36 (1H, s), 7.46 (1H, s), 4.88 (1H, d, J=15.0 Hz),
3.71 (1H, d, J=15.0 Hz), 4.64 (1H, brs), 3.99 (3H, s), 3.94 (3H, s),
3.93 (3H, s), 3.33–3.38 (2H, m), 2.66 (1H, m), 2.49 (1H, m), 2.33
(1H, m), 1.77–1.92 (3H, m), 1.09 (3H, d, J=6.0 Hz), 0.99 (3H, d,
J=6.0 Hz).
13C-NMR (125 MHz, C5D5N): d 158.30, 150.60,
150.10 (overlapped), 133.32, 131.46, 127.08, 126.31, 126.27,
126.23, 124.55, 115.41, 105.31, 104.99, 104.68, 65.57, 56.04,
55.82, 55.75, 55.49, 54.61, 50.56, 45.83, 26.19, 25.19, 24.38,
22.87. HRESIMS calcd for [M+H]
+ C26H33N2O3 421.2486,
found 421.2500. HPLC purity: 99.1% [flow rate 1.0 mL/min,
46% MeCN/H2O (0.08 M NH4H2PO4, 0.2% Et3N)].
(13aR,1 4 S)-14-isopropylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-indolizidine (22)
77% yield. White solid (from MeOH). mp 117–119uC. [a]20 D
243 (c 0.1, CH2Cl2). 99% ee [flow rate 1.0 mL/min, 8%
isopropanol/hexane and 0.2% Et3N, tR (major)=6.48 min, tR
(minor)=7.44 min].
1H-NMR (500 MHz, C5D5N): d 8.69 (1H,
overlapped), 7.45 (1H, dd, overlapped), 8.33 (1H, d, J=2.0 Hz),
8.34 (1H, s), 7.46 (1H, s), 4.74 (1H, d, J=7.0 Hz), 4.65 (1H, d,
J=14.5 Hz), 3.69 (1H, d, J=14.5 Hz), 3.98 (3H, s), 3.95 (3H, s),
3.91 (3H, s), 3.25–3.16 (2H, m), 2.50 (1H, m), 2.34–2.37 (2H, m),
1.78–1.88 (3H, m), 1.27 (3H, d, J=6.0 Hz), 0.96 (3H, d,
J=6.0 Hz). HRESIMS calcd for [M+H]
+ C26H33N2O3
421.2486. found 421.2492. HPLC purity: 99.3% [flow rate
1.0 mL/min, 46% MeCN/H2O (0.08 M NH4H2PO4, 0.2%
Et3N)].
(13aR,1 4 R)-14-isopropylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-indolizidine (23)
73% yield. Light yellow amorphous solid (from acetone/H2O
(1:1)). mp 149–151uC. [a]20 D 265 (c 0.1, CH2Cl2). 99% ee [flow
rate 1.0 mL/min, 8% isopropanol/hexane and 0.2% Et3N, tR
(major)=35.90 min, tR (minor)=17.83 min].
1H-NMR
(500 MHz, C5D5N): d 8.58 (1H, d, J=9.0 Hz), 7.51 (1H, dd,
J=9.0 Hz, 2.0 Hz), 8.38 (1H, d, J=2.0 Hz), 8.36 (1H, s), 7.46
(1H, s), 4.88 (1H, d, J=15.5 Hz), 3.71 (1H, d, J=15.5 Hz), 4.64
(1H, brs), 3.99 (3H, s), 3.94 (3H, s), 3.93 (3H, s), 3.32–3.38 (2H,
m), 2.66 (1H, m), 2.49 (1H, m), 2.33 (1H, m), 1.76–1.94 (3H, m),
1.09 (3H, d, J=6.0 Hz), 0.99 (3H, d, J=6.0 Hz). HRESIMS
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+ C26H33N2O3 421.2486. found 421.2488. HPLC
purity: 98.3% [flow rate 1.0 mL/min, 46% MeCN/H2O (0.08 M
NH4H2PO4, 0.2% Et3N)].
(13aS,1 4 R)-14-cyclopentylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-indolizidine (24)
78% yield.White needles(fromMeOH).mp150–152uC.[a]20 D
+45 (c 0.1, CH2Cl2). 99% ee [flow rate 1.0 mL/min, 8%
isopropanol/hexane and 0.2% Et3N, tR (major)=7.37 min, tR
(minor)=6.23 min].
1H-NMR (500 MHz, C5D5N): d 8.68 (1H, d,
J=9.0 Hz), 7.46 (1H, dd, J=9.0 Hz, 2.5 Hz), 8.33 (1H, d,
J=2.5 Hz), 8.34 (1H, s), 7.47 (1H, s), 4.68 (1H, overlapped), 4.67
(1H,d,J=14Hz),3.72(1H,d,J=14 Hz),3.98 (3H,s),3.95 (3H,s),
3.91 (3H, s), 3.38 (1H, m), 3.26 (1H, brt, J=7.5 Hz), 2.56 (1H, m),
2.35–2.39 (2H, m), 1.71–1.92 (6H, m), 1.49–1.63 (4H, m), 1.36 (1H,
m), 1.21 (1H, m).
13C-NMR (125 MHz, C5D5N): d 158.04, 150.58,
150.10 (overlapped), 131.85, 131.36, 129.00, 128.92, 126.18,
125.81, 124.49, 115.06, 105.29, 104.87, 104.73, 69.43, 59.19,
57.02, 56.03, 55.85, 55.42, 54.59, 53.79, 35.30, 32.86 (62), 24.34,
23.99, 22.65. HRESIMS calcd for [M+H]
+ C28H35N2O3 447.2642,
found 447.2650. HPLC purity: 99.0% [flow rate 1.0 mL/min, 46%
MeCN/H2O( 0 . 0 8MN H 4H2PO4,0 . 2 %E t 3N)].
(13aS,1 4 S)-14-cyclopentylamino-3, 6, 7-
trimethoxyphenanthro [9, 10-b] -indolizidine (25)
74% yield. Light yellow solid (from acetone/H2O (1:1)). mp
112–114uC. [a]20 D +73 (c 0.1, CH2Cl2). 99% ee [flow rate
1.0 mL/min, 8% isopropanol/hexane and 0.2% Et3N, tR
(major)=16.13 min, tR (minor)=40.03 min].
1H-NMR
(500 MHz, C5D5N): d 8.58 (1H, d, J=9.0 Hz), 7.53 (1H, dd,
J=9.0Hz, 2.0 Hz), 8.39 (1H, d, J=2.0 Hz), 8.37 (1H, s), 7.46
(1H, s), 4.88 (1H, d, J=15.5 Hz), 3.72 (1H, d, J=15.5 Hz), 4.58
(1H, brs), 3.99 (3H, s), 3.94 (3H, s), 3.93 (3H, s), 3.52 (1H, m), 3.36
(1H, brt, J=7.5 Hz), 2.67 (1H, m), 2.49 (1H, m), 2.35 (1H, m),
1.83–1.96 (2H, m), 1.71–1.80 (2H, m), 1.50–1.68 (3H, m), 1.43–
1.24 (5H, m).
13C-NMR (125 MHz, C5D5N): d 158.20, 150.48,
150.10 (overlapped), 133.08, 131.27, 127.11, 126.28, 126.19,
126.08, 124.44, 115.29, 105.20, 104.82, 104.56, 65.36, 57.35,
55.94, 55.71, 55.64, 55.38, 54.48, 51.45, 35.56, 34.27, 25.94,
24.38, 24.17, 22.77. HRESIMS calcd for [M+H]
+ C28H35N2O3
447.2642, found 447.2653. HPLC purity: 98.9% [flow rate
1.0 mL/min, 46% MeCN/H2O (0.08 M NH4H2PO4, 0.2%
Et3N)].
(13aR,1 4 S)-14-cyclopentylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-indolizidine (26)
81% yield. White needles (from MeOH). mp 150–152uC. [a]20
D 244 (c 0.1, CH2Cl2). 99% ee [flow rate 1.0 mL/min, 8%
isopropanol/hexane and 0.2% Et3N, tR (major)=6.06 min, tR
(minor)=7.68 min].
1H-NMR (500 MHz, C5D5N): d 8.68 (1H, d,
J=9.0 Hz), 7.46 (1H, overlapped), 8.32 (1H, brs), 8.34 (1H, s),
7.47 (1H, s), 4.68 (1H, overlapped), 4.67 (1H, d, J=14.5 Hz), 3.72
(1H, d, J=14.5 Hz), 3.98 (3H, s), 3.95 (3H, s), 3.91 (3H, s), 3.38
(1H, m), 3.26 (1H, brt, J=7.5 Hz), 2.57 (1H, m), 2.38–2.40 (2H,
m), 1.70–1.88 (6H, m), 1.49–1.64 (4H, m), 1.37 (1H, m), 1.21 (1H,
m). HRESIMS calcd for [M+H]
+ C28H35N2O3 447.2642, found
447.2650. HPLC purity: 98.5% [flow rate 1.0 mL/min, 46%
MeCN/H2O (0.08 M NH4H2PO4, 0.2% Et3N)].
(13aR,1 4 R)-14-cyclopentylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-indolizidine (27)
67% yield. Light yellow solid (from acetone/H2O (1:1)). mp
112–114uC. [a]20 D 273 (c 0.1, CH2Cl2). 100% ee [flow rate
1.0 mL/min, 8% isopropanol/hexane and 0.2% Et3N,
tR=40.11 min].
1H-NMR (500 MHz, C5D5N): d 8.58 (1H, d,
J=9.0 Hz), 7.53 (1H, overlapped), 8.39 (1H, d, J=2.0 Hz), 8.37
(1H, s), 7.46 (1H, s), 4.88 (1H, d, J=15.5 Hz), 3.72 (1H, d,
J=15.5 Hz), 4.58 (1H, brs), 3.99 (3H, s), 3.94 (3H, s), 3.93 (3H, s),
3.53 (1H, brs), 3.36 (1H, brs), 2.67 (1H, m), 2.49 (1H, m), 2.34
(1H, m), 1.88–1.93 (3H, m), 1.74–1.77 (2H, m), 1.54–1.63 (4H, m),
1.27–1.41 (3H, m). HRESIMS calcd for [M+H]
+ C28H35N2O3
447.2642, found 447.2655. HPLC purity: 99.7% [flow rate
1.0 mL/min, 46% MeCN/H2O (0.08 M NH4H2PO4, 0.2%
Et3N)].
(13aS,1 4 R)-14-cyclohexylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-indolizidine (28)
82% yield. White needles (from MeOH). mp 163–165uC. [a]20
D +57 (c 0.1, CH2Cl2). 99% ee [flow rate 1.0 mL/min, 8%
isopropanol/hexane and 0.2% Et3N, tR (major)=7.07 min, tR
(minor)=5.49 min].
1H-NMR (500 MHz, C5D5N): d 8.71 (1H,
overlapped), 7.49 (1H, brd, J=9.0 Hz), 8.33 (1H, brs), 8.34 (1H,
s), 7.46 (1H, s), 4.81 (1H, brs), 4.66 (1H, d, J=14.5 Hz), 3.71 (1H,
d, J=14.5 Hz), 3.98 (3H, s), 3.95 (3H, s), 3.91 (3H, s), 3.25 (1H,
brs), 2.86 (1H, m), 2.54 (1H, m), 2.31–2.39 (3H, m), 1.88–1.91
(2H, m), 1.75–1.78 (2H, m), 1.50–1.65 (4H, m), 1.17–1.34 (3H, m),
1.08–1.12 (2H, m).
13C-NMR (125 MHz, C5D5N): d 158.03,
150.55, 150.10 (overlapped), 131.86, 131.38, 128.97, 128.84,
126.18, 125.75, 124.47, 115.13, 105.27, 104.87, 104.77, 69.99,
57.24, 56.03, 55.84, 55.42, 54.44, 54.05, 53.63, 35.84, 33.30,
32.91, 26.52, 25.58, 25.30, 22.60. HRESIMS calcd for [M+H]
+
C29H37N2O3 461.2799, found 461.2807. HPLC purity: 98.0%
[flow rate 1.0 mL/min, 46% MeCN/H2O (0.08 M NH4H2PO4,
0.2% Et3N)].
(13aS,1 4 S)-14-cyclohexylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-indolizidine (29)
79% yield. Light yellow solid (from acetone/H2O (1:1)). mp
106–108uC. [a]20 D +87 (c 0.1, CH2Cl2). 100% ee [flow rate
1.0 mL/min, 8% isopropanol/hexane and 0.2% Et3N,
tR=15.52 min].
1H-NMR (500 MHz, C5D5N): d 8.59 (1H, d,
J=9.0 Hz), 7.54 (1H, overlapped), 8.37 (1H, brs), 8.35 (1H, s),
7.46 (1H, s), 4.90 (1H, d, J=15.0 Hz), 3.72 (1H, d, J=15.0 Hz),
4.67 (1H, brs), 3.98 (3H, s), 3.94 (3H, s), 3.93 (3H, s), 3.38 (1H, brt,
J=8.0 Hz), 3.00 (1H, m), 2.67 (1H, m), 2.49 (1H, m), 2.35 (1H,
m), 1.73–2.00 (6H, m), 1.63 (1H, m), 1.53 (1H, m), 1.41 (1H, m),
1.13–1.21 (3H, m), 1.04–1.07 (2H, m).
13C-NMR (125 MHz,
C5D5N): d 158.30, 150.58, 150.10 (overlapped), 133.39, 131.48,
127.08, 126.34, 126.26, 126.21, 124.56, 115.42, 105.30, 104.91,
104.66, 65.66, 56.03, 55.81, 55.78, 55.47, 54.69, 54.05, 50.29,
35.65, 35.14, 26.48, 26.30, 25.27, 25.18, 22.91. HRESIMS calcd
for [M+H]
+ C29H37N2O3 461.2799, found 461.2811. HPLC
purity: 99.5% [flow rate 1.0 mL/min, 46% MeCN/H2O (0.08 M
NH4H2PO4, 0.2% Et3N)].
(13aR,1 4 S)-14-cyclohexylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-indolizidine (30)
78% yield. White needles (from MeOH). mp 163–165uC. [a]20
D 255 (c 0.1, CH2Cl2). 99% ee [flow rate 1.0 mL/min, 8%
isopropanol/hexane and 0.2% Et3N, tR (major)=5.43 min, tR
(minor)=7.16 min].
1H-NMR (500 MHz, C5D5N): d 8.71 (1H,
overlapped), 7.49 (1H, brd, J=9.0 Hz), 8.34 (1H, brs), 8.33 (1H,
s), 7.46 (1H, s), 4.81 (1H, d, J=4.0 Hz), 4.66 (1H, d, J=14.5 Hz),
3.71 (1H, d, J=14.5 Hz), 3.98 (3H, s), 3.95 (3H, s), 3.91 (3H, s),
3.25 (1H, brs), 2.85 (1H, m), 2.54 (1H, m), 2.31–2.39 (3H, m),
1.1.89–1.90 (2H, m), 1.76–1.81 (2H, m), 1.50–1.65 (4H, m), 1.17–
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+
C29H37N2O3 461.2799, found 461.2814. HPLC purity: 98.1%
[flow rate 1.0 mL/min, 46% MeCN/H2O (0.08 M NH4H2PO4,
0.2% Et3N)].
(13aR,1 4 R)-14-cyclohexylamino-3, 6, 7-
trimethoxyphenanthro[9, 10-b]-indolizidine (31)
76% yield. Light yellow solid (from acetone/H2O (1:1)). mp
106–108uC. [a]20 D 286 (c 0.1, CH2Cl2). 99% ee [flow rate
1.0 mL/min, 8% isopropanol/hexane and 0.2% Et3N, tR
(major)=30.72 min, tR (minor)=15.92 min].
1H-NMR
(500 MHz, C5D5N): d 8.60 (1H, d, J=9.0 Hz), 7.55 (1H,
overlapped), 8.39 (1H, brs), 8.37 (1H, s), 7.48 (1H, s), 4.91 (1H,
d, J=15.0 Hz), 3.73 (1H, d, J=15.0 Hz), 4.69 (1H, brs), 4.00
(3H, s), 3.96 (3H, s), 3.95 (3H, s), 3.40 (1H, brt, J=8.0 Hz), 3.01
(1H, m), 2.69 (1H, m), 2.53 (1H, m), 2.37 (1H, m), 1.75–2.02 (6H,
m), 1.65 (1H, m), 1.56 (1H, m), 1.42 (1H, m), 1.17–1.22 (3H, m),
1.05–1.09 (2H, m). HRESIMS calcd for [M+H]
+ C29H37N2O3
461.2799, found 461.2813. HPLC purity: 99.8% [flow rate
1.0 mL/min, 46% MeCN/H2O (0.08 M NH4H2PO4, 0.2%
Et3N)].
(13aS,1 4 R)-14-amino-3, 6, 7-trimethoxyphenanthro[9, 10-
b]-indolizidine (32)
To the solution of 12 (0.1 g) in 10 mL of EtOH and 0.5 mL of
concentrated hydrochloric acid was added 10% Pd/C (0.1 g). The
mixture was stirred under H2 at 25 psi for 24 h and then filtered.
The catalyst was washed with 10 mL of water. The filtrate was
combined and evaporated. The residue was dissolved in 5 mL of
water and alkalified to pH 10 with 10% NaOH. The resulting
precipitate was filtered and washed with water. Recrystallized
from acetone/H2O (1:2) gave the product as light yellow solid
(66 mg, 82%). mp 166–168uC (decomposed). [a]20 D +53 (c 0.1,
CH2Cl2). 99% ee [flow rate 1.0 mL/min, 8% isopropanol/hexane
and 0.2% Et3N, tR (major)=20.45 min, tR (minor)=38.40 min].
1H-NMR (500 MHz, C5D5N): d 8.70 (1H, overlapped), 7.40 (1H,
dd, J=9.5 Hz, 2.0 Hz), 8.34 (2H, brs), 7.44 (1H, s), 4.67 (1H, d,
J=15.0 Hz), 3.67 (1H, d, J=15.0 Hz), 4.62 (1H, d, J=7.5 Hz),
3.99 (3H, s), 3.95 (3H, s), 3.90 (3H, s), 3.31 (1H, brt, J=7.5 Hz),
2.29–2.43 (3H, m), 1.98–2.10 (2H, m), 1.87–1.88 (2H, m), 1.77
(1H, m).
13C-NMR (125 MHz, C5D5N): d 157.84, 150.41, 150.10
(overlapped), 133.03, 131.88, 128.63, 127.49, 125.90, 125.28,
124.25, 115.07, 105.09, 104.92, 104.69, 71.35, 55.85, 55.65,
55.37, 55.23, 55.12, 54.66, 30.67, 22.03. HRESIMS calcd for
[M+H]
+ C23H27N2O3 379.2016, found 379.2019. HPLC purity:
99.7% [flow rate 1.0 mL/min, 46% MeCN/H2O (0.08 M
NH4H2PO4, 0.2% Et3N)].
(13aS,1 4 S)-14-amino-3, 6, 7-trimethoxyphenanthro[9, 10-
b]-indolizidine (33)
33 was synthesized under the same reaction condition as 32
from 13. The product was obtained as light yellow solid (from
acetone/H2O (1:2)). 80% yield. mp 133–135uC. [a]20 D +154 (c
0.1, CH2Cl2). 100% ee [flow rate 1.0 mL/min, 26% isopropanol/
hexane and 0.2% Et3N, tR=31.26 min].
1H-NMR (500 MHz,
C5D5N): d 8.53 (1H, d, J=9.0 Hz), 7.45 (1H, brd, J=9.0 Hz),
8.36 (2H, brs), 7.42 (1H, s), 4.76 (1H, d, J=15.0 Hz), 3.68 (1H, d,
J=15.0 Hz), 4.47 (1H, brs), 3.99 (3H, s), 3.93 (3H, s), 3.92 (3H, s),
3.32(1H, brt, J=7.5 Hz), 2.58 (1H, m), 2.30–2.36 (2H, m), 2.12–
2.16 (2H, m), 1.76–1.86 (3H, m).
13C-NMR (125 MHz, C5D5N): d
158.29, 150.54, 150.10 (overlapped), 133.54, 131.72, 126.93,
125.97, 125.80, 125.71, 124.54, 115.95, 105.28, 105.00, 104.66,
65.11, 56.00, 55.79, 55.74, 55.47, 54.80, 48.41, 25.17, 22.92.
HRESIMS calcd for [M+H]
+ C23H27N2O3 379.2016, found
379.2022. HPLC purity: 99.7% [flow rate 1.0 mL/min, 46%
MeCN/H2O (0.08 M NH4H2PO4, 0.2% Et3N)].
(13aR,1 4 S)-14-amino-3, 6, 7-trimethoxyphenanthro[9, 10-
b]-indolizidine (34)
83% yield. Light yellow solid (from acetone/H2O (1:2)). mp
166–168uC (decomposed). [a]20 D 253 (c 0.1, CH2Cl2). 99% ee
[flow rate 1.0 mL/min, 8% isopropanol/hexane and 0.2% Et3N,
tR (major)=38.36 min, tR (minor)=21.01 min].
1H-NMR
(500 MHz, C5D5N): d 8.70 (1H, overlapped), 7.40 (1H, brd,
J=9.0 Hz), 8.34 (2H, brs), 7.43 (1H, s), 4.67 (1H, d, J=14.0 Hz),
3.66 (1H, d, J=14.0 Hz), 4.62 (1H, d, J=6.5 Hz), 3.99 (3H, s),
3.95 (3H, s), 3.90 (3H, s), 3.31 (1H, brs), 2.31–2.41 (3H, m), 1.99–
2.05 (2H, m), 1.86–1.90 (2H, m), 1.74 (1H, m). HRESIMS calcd
for [M+H]
+ C23H27N2O3 379.2016, found 379.2024. HPLC
purity: 98.8% [flow rate 1.0 mL/min, 46% MeCN/H2O (0.08 M
NH4H2PO4, 0.2% Et3N)].
(13aR,1 4 R)-14-amino-3, 6, 7-trimethoxyphenanthro[9,
10-b]-indolizidine (35)
75% yield. Light yellow solid (from acetone/H2O (1:2)). mp
133–135uC. [a]20 D 2156 (c 0.1, CH2Cl2). 100% ee [flow rate
1.0 mL/min, 26% isopropanol/hexane and 0.2% Et3N,
tR=20.13 min].
1H-NMR (500 MHz, C5D5N): d 8.53 (1H, d,
J=9.0 Hz), 7.45 (1H, d, J=9.0 Hz), 8.37 (2H, brs), 7.43 (1H, s),
4.76 (1H, d, J=15.0 Hz), 3.68 (1H, d, J=15.0 Hz), 4.48 (1H,
brs), 3.99 (3H, s), 3.93 (3H, s), 3.92 (3H, s), 3.33(1H, brs), 2.59 (1H,
m), 2.33–2.35 (2H, m), 2.13–2.20 (2H, m), 1.77–1.84 (3H, m).
HRESIMS calcd for [M+H]
+ C23H27N2O3 379.2016, found
379.2019. HPLC purity: 99.7% [flow rate 1.0 mL/min, 46%
MeCN/H2O (0.08 M NH4H2PO4, 0.2% Et3N)].
Cell culture
HCT8, U251, HepG2, A549, A2780, BGC823, and Capan2
were maintained in the RPMI-1640 medium containing 2 g/L
sodium bicarbonate, 10% (v/v) fetal bovine serum (FBS; HyClone,
Logan, UT) supplemented with 100 units/mL of penicillin and
streptomycin (Sigma-Aldrich, St. Louis, MO). All cells were
cultured at 37uC in a humidified incubator with 5% CO2. Test
compounds were dissolved in DMSO (Sigma-Aldrich) to prepare
5 mM stock for the following experiments. The stock was diluted
with culture medium to desired concentrations for drug treatment.
MTT cytotoxicity assay
Doxorubicin (Sigma-Aldrich) was used as the positive control
cytotoxic drug in this experiment. The cytotoxicity of deoxytylo-
phorinine and its derivatives on cells were assessed using MTT
method. HCT8, U251, HepG2, A549, A2780, BGC823 and
Capan2 cells were seeded on 96-well polystyrene cell culture plates
at a density of 2610
4 cells/mL (100 mL). After 24 h attachment,
the cells were treated with six different concentrations of test
compounds for 72 h. After that, the drug containing medium was
removed and replaced by the culture medium with 100 mLo f
0.5 mg/mL MTT (Sigma-Aldrich) solution for 4 h. After that,
formazan formed from MTT was extracted by adding 180 mLo f
DMSO. Absorbance was then determined using a Spectra
Max190 (MD, USA) at 570 nm.
Western blot assay in A549 cells
1, 9, 12, 16, 32, 33, and 35 were added at a final concentration
of 500 nM, and the cell pellets were isolated 24 hours later. And
then A549 cells were washed with PBS and were lysed in 100 mL
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sodium deoxycholate, 0.5 mM sodium orthovanadate, 1% NP-40,
and 0.1% SDS) containing protease inhibitor cocktail and
phosphatase inhibitor cocktail. Clear lysates were obtained by
centrifugation (12,000 rpm for 20 min). Whole-cell lysates were
mixed with 56 sample buffer and heated at 96uC for 10 min.
Then equal amounts of protein per lane were separated by SDS-
PAGE (4% stacker and 10% resolving). Proteins were then
transferred onto nitrocellulose membranes by electroblotting.
Nonspecific binding of the membranes was blocked with Tris-
buffered saline (TBS) containing 5%(w/v) skim milk and 0.1% (v/
v) Tween-20 (TBST) for more than 2 h. And then, the transblotted
membranes were incubated with antibodies of Akt (1:1,000, rabbit
monoclonal antibody; Cell Signaling), ERK (1:500, rabbit
polyclonal antibody; Santa Cruz Biotechnology), cyclin A
(1:2,000, mouse monoclonal antibody; Cell Signaling), cyclin B1
(1:1,000, rabbit monoclonal antibody; oncogene), cyclin D1
(1:500, mouse monoclonal antibody; Santa Cruz Biotechnology),
cyclin E (1:200, rabbit polyclonal antibody; Beijing Biosynthesis
Biotechnology), CDK2 (1:500, rabbit polyclonal antibody; Santa
Cruz Biotechnology), b-actin (1:500, mouse monoclonal antibody;
Santa Cruz Biotechnology) in TBST containing 5% skim milk or
phospho-Akt (Ser473) (1:1,000, rabbit monoclonal antibody; Cell
Signaling), phospho-ERK (Tyr204) (1:500, rabbit polyclonal
antibody; Santa Cruz Biotechnology) in TBST containing 3%
bovine serum albumin (BSA; Sigma-Aldrich) overnight at 4uC.
Subsequently, the membranes were washed with TBST and
incubated for 1.5 h with an appropriate secondary antibody
(1:3,000, horseradish peroxidase-conjugated goat anti-mouse or
anti-rabbit IgG) at room temperature. After washing the
membrane three times for 10 min in TBST, the immunoblots
were visualized by enhanced chemiluminescence using ECL
Western blotting detection reagents and exposed ECL hyperfilm
in Las-3000 (FUJFILM, JP). Multi Gauge v3.0 was used for image
acquisition and data analysis.
Flow cytometric analysis
After 24 h administration of fresh media containing test sample
(1, 9, 32, and 33 at 500 nM), A549 cells were harvested, washed
twice with phospho-buffered saline (PBS) and fixed overnight in
70% EtOH at 4uC. After washing twice with cold PBS, the fixed
cells were then resuspended in 1 ml of cell cycle buffer (50 mg/mL
RNase and 10 mg/mL propidium iodide) for DNA staining at
room temperature for 1 h. DNA content was measured on a
EPICS XL flow cytometer (Beckman Coulter, USA) and the
distribution of cells in the cell cycle was calculated using SYSTEM
II software (BD Biosciences, USA).
Supporting Information
Figure S1 Apoptosis of A549 cells could be induced by
high concentrations of 1.
(DOC)
Figure S2 NOE experiments for compounds l and k. In
the NOE experiments, the NOE association between H-14 (dH
5.19, brs) and H-13a (dH 3.96, m) indicated that the H-14 was cis
to H-13a in compound l. However, for k, the trans-orientation of
H-14 and H-13a was suggested by the NOE association between
H-14 (dH 5.15, d, J=7.0 Hz) and H-13 (dH, 2.23, m) and the
larger coupling contant of H-14 (J=7.0 Hz).
(DOC)
Figure S3 NMR spectra for compounds 1–35.
(DOC)
Figure S4 Purity data for compounds 1–35.
(DOC)
Table S1 Cytotoxic activities of Compounds 1, 9, 12, 16,
32, 33, 35 in A549 cells for 24 h treatment. These data
represent the mean values 6 standard deviation of three
dependent experiments performed in triplicate.
(DOC)
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